

097830446

PCT/CA99/00992


24 FEBRUARY 2000 (24.02.00)

CA 99 / 992

REC'D 08 MAR 2000

WIPO PCT

PA 201867



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 11, 2000

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/107,035

FILING DATE: November 02, 1998

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

*N. Woodson*  
N. WOODSON  
Certifying Officer

A1PROV

11/02/98

105941 U.S. PTO

Please type a plus sign (+) inside this box → ☐

Approved for use through 1/31/98. OMB 0651-0037  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# **PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

105941 U.S. PTO  
60/107035

11/02/98

INVENTOR(S)					
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)	
Andrew D		Murdin		146 Rhodes Circle Newmarket Ontario, Canada L3X 1V2	
Raymond P		Oomen		RR No. 1 Schomberg, Ontario, Canada	
LOG 110					
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto.					
TITLE OF THE INVENTION (280 characters max)					
Chlamydia Antigens and Corresponding DNA Fragments and Uses Thereof					
CORRESPONDENCE ADDRESS					
Direct all correspondence to:					
<input type="checkbox"/> Customer Number		<input type="text"/>		Place Customer Number Bar Code Label here	
OR Type Customer Number here					
<input checked="" type="checkbox"/> Firm or Individual Name		Gavin R. Zealey			
Address		1755 Steeles Ave West			
Address					
City	Toronto	State	Ontario	ZIP	M2R 3T4
Country	Canada	Telephone	416-667-2854	Fax	416-667-2860
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/>	Specification Number of Pages	3132	<input type="checkbox"/>	Small Entity Statement	
<input checked="" type="checkbox"/>	Drawing(s) Number of Sheets	1615	<input type="checkbox"/>	Other (specify)	
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)					
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees					FILING FEE AMOUNT (\$)
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 50-0244					150.00
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE

Date

10/25/98

TYPED or PRINTED NAME

Gavin R. Zealey

REGISTRATION NO.

39,475

(if appropriate)

Docket Number

RY-45

TELEPHONE

416-667-2854

## **USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, DC 20231.

## TITLE OF INVENTION

### CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

## FIELD OF INVENTION

5           The present invention relates to *Chlamydia* antigens and corresponding DNA molecules, which can be used in methods to prevent and treat *Chlamydia* infection in mammals, such as humans.

## BACKGROUND OF THE INVENTION

10           Chlamydiae are prokaryotes. They exhibit morphologic and structural similarities to gram-negative bacteria including a trilaminar outer membrane, which contains lipopolysaccharide and several membrane proteins that are structurally and functionally analogous to proteins found in *E coli*. They are obligate intra-cellular parasites with a unique biphasic life cycle consisting of a metabolically inactive but infectious extracellular stage and a replicating but non-infectious intracellular stage. The replicative stage of the life-cycle  
15           takes place within a membrane-bound inclusion which sequesters the bacteria away from the cytoplasm of the infected host cell.

20           *C. pneumoniae* is a common human pathogen, originally described as the TWAR strain of *Chlamydia psittaci* but subsequently recognised to be a new species. *C. pneumoniae* is antigenically, genetically and morphologically distinct from other chlamydia species (*C. trachomatis*, *C. pecorum* and *C. psittaci*). It shows 10% or less DNA sequence homology with either of *C. trachomatis* or *C. psittaci* and so far appears to consist of only a single strain, TWAR.

25           *C. pneumoniae* is a common cause of community acquired pneumonia, only less frequent than *Streptococcus pneumoniae* and *Mycoplasma pneumoniae* (Ref 1,2). It can also cause upper respiratory tract symptoms and disease, including bronchitis and sinusitis (Ref 1,3,4,5). The great majority of the adult population (over 60%) has antibodies to *C. pneumoniae* (Ref 5), indicating past infection which was unrecognized or asymptomatic.

30           Of considerable importance is the association of atherosclerosis and *C. pneumoniae* infection. There are several epidemiological studies showing a correlation of previous infections with *C. pneumoniae* and heart attacks, coronary artery and carotid artery disease (Ref 6-10). Moreover, the organisms has been detected in atheromas and fatty streaks of the

coronary, carotid, peripheral arteries and aorta (Ref 11-15). Viable *C. pneumoniae* has been recovered from the coronary and carotid artery (Ref 16,17). Furthermore, it has been shown that *C. pneumoniae* can induce changes of atherosclerosis in a rabbit model (Ref 18). Taken together, these results indicate that it is highly probable that *C. pneumoniae* can cause atherosclerosis in humans, though the epidemiological importance of chlamydial atherosclerosis remains to be demonstrated.

A number of recent studies have also indicated an association between *C. pneumoniae* infection and asthma. Infection has been linked to wheezing, asthmatic bronchitis, adult-onset asthma and acute exacerbations of asthma in adults, and small-scale studies have shown that prolonged antibiotic treatment was effective at greatly reducing the severity of the disease in some individuals (Ref 19-24).

In light of these results a protective vaccine against *C. pneumoniae* infection would be of considerable importance. There is not yet an effective vaccine for any human chlamydial infection. Nevertheless, studies with *C. trachomatis* and *C. psittaci* indicate that this is an attainable goal. For example, mice which have recovered from a lung infection with *C. trachomatis* are protected from infertility induced by a subsequent vaginal challenge (Ref 25). Similarly, sheep immunized with inactivated *C. psittaci* were protected from subsequent chlamydial-induced abortions and stillbirths (Ref 26). Protection from chlamydial infections has been associated with Th1 immune responses, particularly the induction of INF $\gamma$  producing CD4 $^{+}$  T-cells (Ref 27). The adoptive transfer of CD4 $^{+}$  cell lines or clones to nude or SCID mice conferred protection from challenge or cleared chronic disease (Ref 28,29), and in vivo depletion of CD4 $^{+}$  T cells exacerbated disease post-challenge (Ref 30,31). However, the presence of sufficiently high titres of neutralising antibody at mucosal surfaces can also exert a protective effect (Ref 32).

The extent of antigenic variation within the species *C. pneumoniae* is not well characterised. Serovars of *C. trachomatis* are defined on the basis of antigenic variation in MOMP, but published *C. pneumoniae* MOMP gene sequences show no variation between several diverse isolates of the organism (Ref 33-35). Regions of the protein known to be conserved in other chlamydial MOMP are conserved in *C. pneumoniae* (Ref 33,34). One study has described a strain of *C. pneumoniae* with a MOMP of greater than usual molecular weight, but the gene for this has not been sequenced (Ref 36). Partial sequences of outer

membrane protein 2 from nine diverse isolates were also found to be invariant (Ref 16). The genes for HSP60 and HSP70 show little variation from other chlamydial species, as would be expected. The gene encoding a 76kDa antigen has been cloned from a single strain of *C. pneumoniae*. It has no significant similarity with other known chlamydial genes (Ref 4).

5 Many antigens recognised by immune sera to *C. pneumoniae* are conserved across all chlamydiae, but 98kDa, 76 kDa and 54 kDa proteins may be *C. pneumoniae*-specific (Ref 2, 4, 36). Immunoblotting of isolates with sera from patients does show variation of blotting patterns between isolates, indicating that serotypes *C. pneumoniae* may exist (Ref 1,16). However, the results are potentially confounded by the infection status of the patients, since  
10 immunoblot profiles of a patient's sera change with time post-infection. An assessment of the number and relative frequency of any serotypes, and the defining antigens, is not yet possible.

*C. pneumoniae* infection usually presents as an acute respiratory disease (i.e., cough, sore throat, hoarseness, and fever; abnormal chest sounds on auscultation). For most patients, the cough persists for 2 to 6 weeks, and recovery is slow. In approximately 10% of these  
15 cases, upper respiratory tract infection is followed by bronchitis or pneumonia. Furthermore, during a *C. pneumoniae* epidemic, subsequent co-infection with pneumococcus has been noted in about half of these pneumonia patients, particularly in the infirm and the elderly. As noted above, there is more and more evidence that *C. pneumoniae* infection is also linked to diseases other than respiratory infections.

20 The reservoir for the organism is presumably people. In contrast to *C. psittaci* infections, there is no known bird or animal reservoir. Transmission has not been clearly defined. It may result from direct contact with secretions, from fomites, or from airborne spread. There is a long incubation period, which may last for many months. Based on analysis of epidemics, *C. pneumoniae* appears to spread slowly through a population (case-to-  
25 case interval averaging 30 days) because infected persons are inefficient transmitters of the organism. Susceptibility to *C. pneumoniae* is universal. Reinfections occur during adulthood, following the primary infection as a child. *C. pneumoniae* appears to be an endemic disease throughout the world, noteworthy for superimposed intervals of increased incidence (epidemics) that persist for 2 to 3 years. *C. trachomatis* infection does not confer cross-  
30 immunity to *C. pneumoniae*. Infections are easily treated with oral antibiotics, tetracycline or

erythromycin (2 g/d, for at least 10 to 14 d). A recently developed drug, azithromycin, is highly effective as a single-dose therapy against chlamydial infections.

In most instances, *C. pneumoniae* infection is often mild and without complications, and up to 90% of infections are subacute or unrecognized. Among children in industrialized countries, infections have been thought to be rare up to the age of 5 y, although a recent study (E Normann et al, Chlamydia pneumoniae in children with acute respiratory tract infections, Acta Paediatrica, 1998; Vol 87, Iss 1, pp 23-27) has reported that many children in this age group show PCR evidence of infection despite being seronegative, and estimates a prevalence of 17-19% in 2-4 y olds. In developing countries, the seroprevalence of *C. pneumoniae* antibodies among young children is elevated, and there are suspicions that *C. pneumoniae* may be an important cause of acute lower respiratory tract disease and mortality for infants and children in tropical regions of the world.

From seroprevalence studies and studies of local epidemics, the initial *C. pneumoniae* infection usually happens between the ages of 5 and 20 y. In the USA, for example, there are estimated to be 30,000 cases of childhood pneumonia each year caused by *C. pneumoniae*. Infections may cluster among groups of children or young adults (e.g., school pupils or military conscripts).

*C. pneumoniae* causes 10 to 25% of community-acquired lower respiratory tract infections (as reported from Sweden, Italy, Finland, and the USA). During an epidemic, *C. pneumoniae* infection may account for 50 to 60% of the cases of pneumonia. During these periods, also, more episodes of mixed infections with *S. pneumoniae* have been reported. Reinfection during adulthood is common; the clinical presentation tends to be milder. Based on population seroprevalence studies, there tends to be increased exposure with age, which is particularly evident among men. Some investigators have speculated that a persistent, asymptomatic *C. pneumoniae* infection state is common.

In adults of middle age or older, *C. pneumoniae* infection may progress to chronic bronchitis and sinusitis. A study in the USA revealed that the incidence of pneumonia caused by *C. pneumoniae* in persons younger than 60 years is 1 case per 1,000 persons per year; but in the elderly, the disease incidence rose three-fold. *C. pneumoniae* infection rarely leads to hospitalization, except in patients with an underlying illness.

### SUMMARY OF THE INVENTION

The present invention provides purified and isolated DNA molecules that encode *Chlamydia* polypeptides designated CPN100626 (SEQ ID No: 1,2), which can be used in methods to prevent, treat, and diagnose *Chlamydia* infection. The encoded polypeptides include polypeptides having the amino acid sequence shown in SEQ ID No:3. Those skilled in the art will appreciate that the invention also includes DNA molecules that encode mutants and derivatives of such polypeptides, which result from the addition, deletion, or substitution of non-essential amino acids as described herein. The invention also includes RNA molecules corresponding to the DNA molecules of the invention.

In addition to the DNA and RNA molecules, the invention includes the corresponding polypeptides and monospecific antibodies that specifically bind to such polypeptides.

The present invention has wide application and includes expression cassettes, vectors, and cells transformed or transfected with the polynucleotides of the invention. Accordingly, the present invention provides (i) a method for producing a polypeptide of the invention in a recombinant host system and related expression cassettes, vectors, and transformed or transfected cells; (ii) a live vaccine vector, such as a pox virus, *Salmonella typhimurium*, or *Vibrio cholerae* vector, containing a polynucleotide of the invention, such vaccine vectors being useful for, e.g., preventing and treating *Chlamydia* infection, in combination with a diluent or carrier, and related pharmaceutical compositions and associated therapeutic and/or prophylactic methods; (iii) a therapeutic and/or prophylactic method involving administration of an RNA or DNA molecule of the invention, either in a naked form or formulated with a delivery vehicle, a polypeptide or combination of polypeptides, or a monospecific antibody of the invention, and related pharmaceutical compositions; (iv) a method for diagnosing the presence of *Chlamydia* in a biological sample, which can involve the use of a DNA or RNA molecule, a monospecific antibody, or a polypeptide of the invention; and (v) a method for purifying a polypeptide of the invention by antibody-based affinity chromatography.

### BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further understood from the following description with reference to the drawings, in which:

Figure 1 shows the nucleotide sequence of the CPN100626 (SEQ ID No: 1 - entire sequence and SEQ ID No: 2 - coding sequence). The protein is encoded on the negative strand.

Figure 2 shows the deduced amino acid sequence of the CPN100626 protein from *Chlamydia pneumoniae* (SEQ ID No: 3). The protein is encoded on the negative strand.

Figure 3 shows the restriction enzyme analysis of the gene encoding the *C. pneumoniae* CPN100626 gene.

#### DETAILED DESCRIPTION OF INVENTION

In the *C. pneumoniae* genome, open reading frames (ORFs) encoding chlamydial polypeptides have been identified. These polypeptides include polypeptides permanently found in the bacterial membrane structure, polypeptides that are present in the external vicinity of the bacterial membrane, include polypeptides permanently found in the inclusion membrane structure, polypeptides that are present in the external vicinity of the inclusion membrane, and polypeptides that are released into the cytoplasm of the infected cell. These polypeptides can be used in vaccination methods for preventing and treating *Chlamydia* infection.

According to a first aspect of the invention, there are provided isolated polynucleotides encoding the precursor and mature forms of *Chlamydia* polypeptides.

An isolated polynucleotide of the invention encodes (i) a polypeptide having an amino acid sequence that is homologous to a *Chlamydia* amino acid, the *Chlamydia* amino acid sequence being selected from the group consisting of:

(a) the amino acid sequences as shown (SEQ ID No: 3)

The term "isolated polynucleotide" is defined as a polynucleotide removed from the environment in which it naturally occurs. For example, a naturally-occurring DNA molecule present in the genome of a living bacteria or as part of a gene bank is not isolated, but the same molecule separated from the remaining part of the bacterial genome, as a result of, e.g., a cloning event (amplification), is isolated. Typically, an isolated DNA molecule is free from DNA regions (e.g., coding regions) with which it is immediately contiguous at the 5' or 3' end, in the naturally occurring genome. Such isolated polynucleotides could be part of a vector or a composition and still be isolated in that such a vector or composition is not part of its natural environment.



A polynucleotide of the invention can be in the form of RNA or DNA (*e.g.*, cDNA, genomic DNA, or synthetic DNA), or modifications or combinations thereof. The DNA can be double-stranded or single-stranded, and, if single-stranded, can be the coding strand or the non-coding (anti-sense) strand. The sequence that encodes a polypeptide of the invention as shown in SEQ ID NOs: 1 and 2, can be (a) the coding sequence as shown in SEQ ID NOs:2 (b) a ribonucleotide sequence derived by transcription of (a) ; or (c) a different coding sequence; this latter, as a result of the redundancy or degeneracy of the genetic code, encodes the same polypeptides as the DNA molecules of which the nucleotide sequences are illustrated in SEQ ID NOs:1 to 2.

By "polypeptide" or "protein" is meant any chain of amino acids, regardless of length or post-translational modification (*e.g.*, glycosylation or phosphorylation). Both terms are used interchangeably in the present application.

By "homologous amino acid sequence" is meant an amino acid sequence that differs from an amino acid sequence shown in SEQ ID No: 3, only by one or more conservative amino acid substitutions, or by one or more non-conservative amino acid substitutions, deletions, or additions located at positions at which they do not destroy the specific antigenicity of the polypeptide.

Preferably, such a sequence is at least 75%, more preferably 80%, and most preferably 90% identical to an amino acid sequence shown in SEQ ID No: 3.

Homologous amino acid sequences include sequences that are identical or substantially identical to an amino acid sequence as shown in SEQ ID No:3. By "amino acid sequence substantially identical" is meant a sequence that is at least 90%, preferably 95%, more preferably 97%, and most preferably 99% identical to an amino acid sequence of reference and that preferably differs from the sequence of reference, if at all, by a majority of conservative amino acid substitutions.

Conservative amino acid substitutions typically include substitutions among amino acids of the same class. These classes include, for example, amino acids having uncharged polar side chains, such as asparagine, glutamine, serine, threonine, and tyrosine; amino acids having basic side chains, such as lysine, arginine, and histidine; amino acids having acidic side chains, such as aspartic acid and glutamic acid; and amino acids having nonpolar side chains,

such as glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, and cysteine.

Homology is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Similar amino acid sequences are aligned to obtain the maximum degree of homology (i.e., identity). To this end, it may be necessary to artificially introduce gaps into the sequence. Once the optimal alignment has been set up, the degree of homology (i.e., identity) is established by recording all of the positions in which the amino acids of both sequences are identical, relative to the total number of positions.

Homologous polynucleotide sequences are defined in a similar way. Preferably, a homologous sequence is one that is at least 45%, more preferably 60%, and most preferably 85% identical to (i) a coding sequence of SEQ ID NOs:1 and 2.

Polypeptides having a sequence homologous to one of the sequences shown in SEQ ID NO: 3, include naturally occurring allelic variants, as well as mutants or any other non-naturally occurring variants that are analogous in terms of antigenicity, to a polypeptide having a sequence as shown in SEQ ID NO: 3.

As is known in the art, an allelic variant is an alternate form of a polypeptide that is characterized as having a substitution, deletion, or addition of one or more amino acids that does not alter the biological function of the polypeptide. By "biological function" is meant the function of the polypeptide in the cells in which it naturally occurs, even if the function is not necessary for the growth or survival of the cells. For example, the biological function of a porin is to allow the entry into cells of compounds present in the extracellular medium. The biological function is distinct from the antigenic function. A polypeptide can have more than one biological function.

Allelic variants are very common in nature. For example, a bacterial species, e.g., *C. pneumoniae*, is usually represented by a variety of strains that differ from each other by minor allelic variations. Indeed, a polypeptide that fulfills the same biological function in different strains can have an amino acid sequence that is not identical in each of the strains. Such an allelic variation may be equally reflected at the polynucleotide level.

Support for the use of allelic variants of polypeptide antigens comes from, *e.g.*, studies of the *Chlamydial* MOMP antigen. The amino acid sequence of the MOMP varies from strain to strain, yet cross-strain antibody binding plus neutralization of infectivity occurs, indicating that the MOMP, when used as an immunogen, is tolerant of amino acid variations.

Polynucleotides, *e.g.*, DNA molecules, encoding allelic variants can easily be retrieved by polymerase chain reaction (PCR) amplification of genomic bacterial DNA extracted by conventional methods. This involves the use of synthetic oligonucleotide primers matching upstream and downstream of the 5' and 3' ends of the encoding domain. Suitable primers can be designed according to the nucleotide sequence information provided in SEQ ID NOs:1 and 2. Typically, a primer can consist of 10 to 40, preferably 15 to 25 nucleotides. It may be also advantageous to select primers containing C and G nucleotides in a proportion sufficient to ensure efficient hybridization; *e.g.*, an amount of C and G nucleotides of at least 40%, preferably 50% of the total nucleotide amount.

Useful homologs that do not naturally occur can be designed using known methods for identifying regions of an antigen that are likely to be tolerant of amino acid sequence changes and/or deletions. For example, sequences of the antigen from different species can be compared to identify conserved sequences.

Polypeptide derivatives that are encoded by polynucleotides of the invention include, *e.g.*, fragments, polypeptides having large internal deletions derived from full-length polypeptides, and fusion proteins.

Polypeptide fragments of the invention can be derived from a polypeptide having a sequence homologous to any of the sequences shown in SEQ ID NO: 3, to the extent that the fragments retain the substantial antigenicity of the parent polypeptide (specific antigenicity). Polypeptide derivatives can also be constructed by large internal deletions that remove a substantial part of the parent polypeptide, while retaining specific antigenicity. Generally, polypeptide derivatives should be about at least 12 amino acids in length to maintain antigenicity. Advantageously, they can be at least 20 amino acids, preferably at least 50 amino acids, more preferably at least 75 amino acids, and most preferably at least 100 amino acids in length.

Useful polypeptide derivatives, *e.g.*, polypeptide fragments, can be designed using computer-assisted analysis of amino acid sequences in order to identify sites in protein antigens having potential as surface-exposed, antigenic regions (Ref 37).

Polypeptide fragments and polypeptides having large internal deletions can be used for revealing epitopes that are otherwise masked in the parent polypeptide and that may be of importance for inducing a protective T cell-dependent immune response. Deletions can also remove immunodominant regions of high variability among strains.

It is an accepted practice in the field of immunology to use fragments and variants of protein immunogens as vaccines, as all that is required to induce an immune response to a protein is a small (*e.g.*, 8 to 10 amino acid) immunogenic region of the protein. This has been done for a number of vaccines against pathogens other than *Chlamydia*. For example, short synthetic peptides corresponding to surface-exposed antigens of pathogens such as murine mammary tumor virus, peptide containing 11 amino acids; (Ref 38), Semliki Forest virus, peptide containing 16 amino acids (Ref 39), and canine parvovirus, 2 overlapping peptides, each containing 15 amino acids (Ref 40), have been shown to be effective vaccine antigens against their respective pathogens.

Polynucleotides encoding polypeptide fragments and polypeptides having large internal deletions can be constructed using standard methods (Ref 41), for example, by PCR, including inverse PCR, by restriction enzyme treatment of the cloned DNA molecules, or by the method of Kunkel *et al.* (Ref 42) biological material available at Stratagene.

A polypeptide derivative can also be produced as a fusion polypeptide that contains a polypeptide or a polypeptide derivative of the invention fused, *e.g.*, at the N- or C-terminal end, to any other polypeptide (hereinafter referred to as a peptide tail). Such a product can be easily obtained by translation of a genetic fusion, *i.e.*, a hybrid gene. Vectors for expressing fusion polypeptides are commercially available, such as the pMal-c2 or pMal-p2 systems of New England Biolabs, in which the peptide tail is a maltose binding protein, the glutathione-S-transferase system of Pharmacia, or the His-Tag system available from Novagen. These and other expression systems provide convenient means for further purification of polypeptides and derivatives of the invention.

Another particular example of fusion polypeptides included in invention includes a polypeptide or polypeptide derivative of the invention fused to a polypeptide having adjuvant

activity, such as, *e.g.*, subunit B of either cholera toxin or *E. coli* heat-labile toxin. Several possibilities are can be used for achieving fusion. First, the polypeptide of the invention can be fused to the N-, or preferably, to the C-terminal end of the polypeptide having adjuvant activity. Second, a polypeptide fragment of the invention can be fused within the amino acid sequence of the polypeptide having adjuvant activity.

As stated above, the polynucleotides of the invention encode *Chlamydia* polypeptides in precursor or mature form. They can also encode hybrid precursors containing heterologous signal peptides, which can mature into polypeptides of the invention. By "heterologous signal peptide" is meant a signal peptide that is not found in the naturally-occurring precursor of a polypeptide of the invention.

A polynucleotide of the invention, having a homologous coding sequence, hybridizes, preferably under stringent conditions, to a polynucleotide having a sequence as shown in SEQ ID NOs:1 to 2. Hybridization procedures are, *e.g.*, described in Ausubel *et al.*, (Ref 41), Silhavy *et al.* (Ref 43); Davis *et al.* (ref 44). Important parameters that can be considered for optimizing hybridization conditions are reflected in a formula that allows calculation of a critical value, the melting temperature above which two complementary DNA strands separate from each other Ref 45). This formula is as follows:  $T_m = 81.5 + 0.5 \times (\% G+C) + 1.6 \log (\text{positive ion concentration}) - 0.6 \times (\% \text{ formamide})$ . Under appropriate stringency conditions, hybridization temperature ( $T_h$ ) is approximately 20 to 40°C, 20 to 25°C, or, preferably 30 to 40°C below the calculated  $T_m$ . Those skilled in the art will understand that optimal temperature and salt conditions can be readily determined empirically in preliminary experiments using conventional procedures.

For example, stringent conditions can be achieved, both for pre-hybridizing and hybridizing incubations, (i) within 4-16 hours at 42°C, in 6 x SSC containing 50% formamide or (ii) within 4-16 hours at 65°C in an aqueous 6 x SSC solution (1 M NaCl, 0.1 M sodium citrate (pH 7.0)).

For polynucleotides containing 30 to 600 nucleotides, the above formula is used and then is corrected by subtracting (600/polynucleotide size in base pairs). Stringency conditions are defined by a  $T_h$  that is 5 to 10°C below  $T_m$ .

Hybridization conditions with oligonucleotides shorter than 20-30 bases do not exactly follow the rules set forth above. In such cases, the formula for calculating the  $T_m$  is

as follows:  $T_m = 4 \times (G+C) + 2 \times (A+T)$ . For example, an 18 nucleotide fragment of 50% G+C would have an approximate  $T_m$  of 54°C.

A polynucleotide molecule of the invention, containing RNA, DNA, or modifications or combinations thereof, can have various applications. For example, a DNA molecule can be used (i) in a process for producing the encoded polypeptide in a recombinant host system, (ii) in the construction of vaccine vectors such as poxviruses, which are further used in methods and compositions for preventing and/or treating *Chlamydia* infection, (iii) as a vaccine agent (as well as an RNA molecule), in a naked form or formulated with a delivery vehicle and, (iv) in the construction of attenuated *Chlamydia* strains that can over-express a polynucleotide of the invention or express it in a non-toxic, mutated form.

According to a second aspect of the invention, there is therefore provided (i) an expression cassette containing a DNA molecule of the invention placed under the control of the elements required for expression, in particular under the control of an appropriate promoter; (ii) an expression vector containing an expression cassette of the invention; (iii) a procaryotic or eucaryotic cell transformed or transfected with an expression cassette and/or vector of the invention, as well as (iv) a process for producing a polypeptide or polypeptide derivative encoded by a polynucleotide of the invention, which involves culturing a procaryotic or eucaryotic cell transformed or transfected with an expression cassette and/or vector of the invention, under conditions that allow expression of the DNA molecule of the invention and, recovering the encoded polypeptide or polypeptide derivative from the cell culture.

A recombinant expression system can be selected from procaryotic and eucaryotic hosts. Eucaryotic hosts include yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris*), mammalian cells (e.g., COS1, NIH3T3, or JEG3 cells), arthropods cells (e.g., *Spodoptera frugiperda* (SF9) cells), and plant cells. Preferably, a procaryotic host such as *E. coli* is used. Bacterial and eucaryotic cells are available from a number of different sources to those skilled in the art, e.g., the American Type Culture Collection (ATCC; Rockville, Maryland).

The choice of the expression system depends on the features desired for the expressed polypeptide. For example, it may be useful to produce a polypeptide of the invention in a particular lipidated form or any other form.

The choice of the expression cassette will depend on the host system selected as well as the features desired for the expressed polypeptide. Typically, an expression cassette includes a promoter that is functional in the selected host system and can be constitutive or inducible; a ribosome binding site; a start codon (ATG) if necessary, a region encoding a signal peptide, *e.g.*, a lipidation signal peptide; a DNA molecule of the invention; a stop codon; and optionally a 3' terminal region (translation and/or transcription terminator). The signal peptide encoding region is adjacent to the polynucleotide of the invention and placed in proper reading frame. The signal peptide-encoding region can be homologous or heterologous to the DNA molecule encoding the mature polypeptide and can be specific to the secretion apparatus of the host used for expression. The open reading frame constituted by the DNA molecule of the invention, solely or together with the signal peptide, is placed under the control of the promoter so that transcription and translation occur in the host system. Promoters, signal peptide encoding regions are widely known and available to those skilled in the art and includes, for example, the promoter of *Salmonella typhimurium* (and derivatives) that is inducible by arabinose (promoter *araB*) and is functional in Gram-negative bacteria such as *E. coli* (as described in U.S. Patent No. 5,028,530 and in Cagnon *et al.*, (Ref 46); the promoter of the gene of bacteriophage T7 encoding RNA polymerase, that is functional in a number of *E. coli* strains expressing T7 polymerase (described in U.S. Patent No. 4,952,496); ~~OspA lipidation signal peptide, and RlpB lipidation signal peptide (Ref 47).~~

The expression cassette is typically part of an expression vector, which is selected for its ability to replicate in the chosen expression system. Expression vectors (*e.g.*, plasmids or viral vectors) can be chosen from those described in Pouwels *et al.* (Cloning Vectors: A Laboratory Manual 1985, Supp. 1987). They can be purchased from various commercial sources.

Methods for transforming/transfecting host cells with expression vectors will depend on the host system selected as described in Ausubel *et al.*, (Ref 41).

Upon expression, a recombinant polypeptide of the invention (or a polypeptide derivative) is produced and remains in the intracellular compartment, is secreted/excreted in the extracellular medium or in the periplasmic space, or is embedded in the cellular membrane. The polypeptide can then be recovered in a substantially purified form from the cell extract or from the supernatant after centrifugation of the recombinant cell culture.

Typically, the recombinant polypeptide can be purified by antibody-based affinity purification or by any other method that can be readily adapted by a person skilled in the art, such as by genetic fusion to a small affinity binding domain. Antibody-based affinity purification methods are also available for purifying a polypeptide of the invention extracted from a *Chlamydia* strain. Antibodies useful for purifying by immunoaffinity the polypeptides of the invention can be obtained as described below.

A polynucleotide of the invention can also be useful in the vaccine field, *e.g.*, for achieving DNA vaccination. There are two major possibilities, either using a viral or bacterial host as gene delivery vehicle (live vaccine vector) or administering the gene in a free form, *e.g.*, inserted into a plasmid. Therapeutic or prophylactic efficacy of a polynucleotide of the invention can be evaluated as described below.

Accordingly, in a third aspect of the invention, there is provided (i) a vaccine vector such as a poxvirus, containing a DNA molecule of the invention, placed under the control of elements required for expression; (ii) a composition of matter containing a vaccine vector of the invention, together with a diluent or carrier, particularly, (iii) a pharmaceutical composition containing a therapeutically or prophylactically effective amount of a vaccine vector of the invention; (iv) a method for inducing an immune response against *Chlamydia* in a mammal (*e.g.*, a human; alternatively, the method can be used in veterinary applications for treating or preventing *Chlamydia* infection of animals, *e.g.*, cats or birds), which involves administering to the mammal an immunogenically effective amount of a vaccine vector of the invention to elicit an immune response, *e.g.*, a protective or therapeutic immune response to *Chlamydia*; and particularly, (v) a method for preventing and/or treating a *Chlamydia* (*e.g.*, *C. trachomatis*, *C. psittaci*, *C. pneumonia*, *C. pecorum*) infection, which involves administering a prophylactic or therapeutic amount of a vaccine vector of the invention to an individual in need. Additionally, the third aspect of the invention encompasses the use of a vaccine vector of the invention in the preparation of a medicament for preventing and/or treating *Chlamydia* infection.

A vaccine vector of the invention can express one or several polypeptides or derivatives of the invention, as well as at least one additional *Chlamydia* antigen, fragment, homolog, mutant, or derivative thereof. In addition, it can express a cytokine, such as interleukin-2 (IL-2) or interleukin-12 (IL-12), that enhances the immune response (adjuvant



effect). Thus, a vaccine vector can include an additional DNA sequence encoding, *e.g.*, a chlamydial antigen, or a cytokine, placed under the control of elements required for expression in a mammalian cell.

Alternatively, a composition of the invention can include several vaccine vectors, each of them being capable of expressing a polypeptide or derivative of the invention. A composition can also contain a vaccine vector capable of expressing an additional *Chlamydia* antigen, or a subunit, fragment, homolog, mutant, or derivative thereof; or a cytokine such as IL-2 or IL-12.

In vaccination methods for treating or preventing infection in a mammal, a vaccine vector of the invention can be administered by any conventional route in use in the vaccine field, particularly, to a mucosal (*e.g.*, ocular, intranasal, oral, gastric, pulmonary, intestinal, rectal, vaginal, or urinary tract) surface or *via* the parenteral (*e.g.*, subcutaneous, intradermal, intramuscular, intravenous, or intraperitoneal) route. Preferred routes depend upon the choice of the vaccine vector. The administration can be achieved in a single dose or repeated at intervals. The appropriate dosage depends on various parameters understood by skilled artisans such as the vaccine vector itself, the route of administration or the condition of the mammal to be vaccinated (weight, age and the like).

Live vaccine vectors available in the art include viral vectors such as adenoviruses and poxviruses as well as bacterial vectors, *e.g.*, *Shigella*, *Salmonella*, *Vibrio cholerae*, *Lactobacillus*, Bacille bilié de Calmette-Guérin (BCG), and *Streptococcus*.

An example of an adenovirus vector, as well as a method for constructing an adenovirus vector capable of expressing a DNA molecule of the invention, are described in U.S. Patent No. 4,920,209. Poxvirus vectors that can be used include, *e.g.*, vaccinia and canary pox virus, described in U.S. Patent No. 4,722,848 and U.S. Patent No. 5,364,773, respectively (also see, *e.g.*, Tartaglia *et al.*, Virology (1992) 188:217) for a description of a vaccinia virus vector; and Taylor *et al.*, Vaccine (1995) 13:539 for a reference of a canary pox). Poxvirus vectors capable of expressing a polynucleotide of the invention can be obtained by homologous recombination as described in Kieny *et al.*, Nature (1984) 312:163 so that the polynucleotide of the invention is inserted in the viral genome under appropriate conditions for expression in mammalian cells. Generally, the dose of vaccine viral vector, for therapeutic or prophylactic use, can be of from about  $1 \times 10^4$  to about  $1 \times 10^{11}$ , advantageously

from about  $1 \times 10^7$  to about  $1 \times 10^{10}$ , preferably of from about  $1 \times 10^7$  to about  $1 \times 10^9$  plaque-forming units per kilogram. Preferably, viral vectors are administered parenterally; for example, in 3 doses, 4 weeks apart. Those skilled in the art recognize that it is preferable to avoid adding a chemical adjuvant to a composition containing a viral vector of the invention and thereby minimizing the immune response to the viral vector itself.

Non-toxicogenic *Vibrio cholerae* mutant strains that are useful as a live oral vaccine are described in Mekalanos *et al.*, Nature (1983) 306:551 and U.S. Patent No. 4,882,278 (strain in which a substantial amount of the coding sequence of each of the two *ctxA* alleles has been deleted so that no functional *cholerae* toxin is produced); WO 92/11354 (strain in which the *irgA* locus is inactivated by mutation; this mutation can be combined in a single strain with *ctxA* mutations); and WO 94/1533 (deletion mutant lacking functional *ctxA* and *attRS1* DNA sequences). These strains can be genetically engineered to express heterologous antigens, as described in WO 94/19482. An effective vaccine dose of a *Vibrio cholerae* strain capable of expressing a polypeptide or polypeptide derivative encoded by a DNA molecule of the invention can contain, e.g., about  $1 \times 10^5$  to about  $1 \times 10^9$ , preferably about  $1 \times 10^6$  to about  $1 \times 10^8$  viable bacteria in an appropriate volume for the selected route of administration. Preferred routes of administration include all mucosal routes; most preferably, these vectors are administered intranasally or orally.

~~Attenuated *Salmonella typhimurium* strains, genetically engineered for recombinant expression of heterologous antigens or not, and their use as oral vaccines are described in Nakayama *et al.* (Bio/Technology (1988) 6:693) and WO 92/11361. Preferred routes of administration include all mucosal routes; most preferably, these vectors are administered intranasally or orally.~~

Others bacterial strains useful as vaccine vectors are described in High *et al.*, EMBO (1992) 11:1991 and Sizemore *et al.*, Science (1995) 270:299 (*Shigella flexneri*); Medaglini *et al.*, Proc. Natl. Acad. Sci. USA (1995) 92:6868 (*Streptococcus gordonii*); and Flynn J.L., Cell. Mol. Biol. (1994) 40 (suppl. I):31, WO 88/6626, WO 90/0594, WO 91/13157, WO 92/1796, and WO 92/21376 (*Bacille Calmette-Guerin*).

In bacterial vectors, polynucleotides of the invention can be inserted into the bacterial genome or can remain in a free state, carried on a plasmid.

An adjuvant can also be added to a composition containing a vaccine bacterial vector. A number of adjuvants are known to those skilled in the art. Preferred adjuvants can be selected from the list provided below.

According to a fourth aspect of the invention, there is also provided (i) a composition of matter containing a polynucleotide of the invention, together with a diluent or carrier; (ii) a pharmaceutical composition containing a therapeutically or prophylactically effective amount of a polynucleotide of the invention; (iii) a method for inducing an immune response against *Chlamydia*, in a mammal, by administering to the mammal, an immunogenically effective amount of a polynucleotide of the invention to elicit an immune response, *e.g.*, a protective immune response to *Chlamydia*; and particularly, (iv) a method for preventing and/or treating a *Chlamydia* (*e.g.*, *C. trachomatis*, *C. psittaci*, *C. pneumoniae*, or *C. pecorum*) infection, by administering a prophylactic or therapeutic amount of a polynucleotide of the invention to an individual in need. Additionally, the fourth aspect of the invention encompasses the use of a polynucleotide of the invention in the preparation of a medicament for preventing and/or treating *Chlamydia* infection. The fourth aspect of the invention preferably includes the use of a DNA molecule placed under conditions for expression in a mammalian cell, *e.g.*, in a plasmid that is unable to replicate in mammalian cells and to substantially integrate in a mammalian genome.

Polynucleotides (DNA or RNA) of the invention can also be administered as such to a mammal for vaccine, *e.g.*, therapeutic or prophylactic, purpose. When a DNA molecule of the invention is used, it can be in the form of a plasmid that is unable to replicate in a mammalian cell and unable to integrate in the mammalian genome. Typically, a DNA molecule is placed under the control of a promoter suitable for expression in a mammalian cell. The promoter can function ubiquitously or tissue-specifically. Examples of non-tissue specific promoters include the early Cytomegalovirus (CMV) promoter (described in U.S. Patent No. 4,168,062) and the Rous Sarcoma Virus promoter (described in Norton & Coffin, *Molec. Cell Biol.* (1985) 5:281). The desmin promoter (Li *et al.*, *Gene* (1989) 78:243, Li & Paulin, *J. Biol. Chem.* (1991) 266:6562 and Li & Paulin, *J. Biol. Chem.* (1993) 268:10403) is tissue-specific and drives expression in muscle cells. More generally, useful vectors are described, *i.a.*, WO 94/21797 and Hartikka *et al.*, *Human Gene Therapy* (1996) 7:1205.

For DNA/RNA vaccination, the polynucleotide of the invention can encode a precursor or a mature form. When it encodes a precursor form, the precursor form can be homologous or heterologous. In the latter case, a eucaryotic leader sequence can be used, such as the leader sequence of the tissue-type plasminogen factor (tPA).

5 A composition of the invention can contain one or several polynucleotides of the invention. It can also contain at least one additional polynucleotide encoding another *Chlamydia* antigen such as urease subunit A, B, or both; or a fragment, derivative, mutant, or analog thereof. A polynucleotide encoding a cytokine, such as interleukin-2 (IL-2) or interleukin-12 (IL-12), can also be added to the composition so that the immune response is  
10 enhanced. These additional polynucleotides are placed under appropriate control for expression. Advantageously, DNA molecules of the invention and/or additional DNA molecules to be included in the same composition, can be carried in the same plasmid.

Standard techniques of molecular biology for preparing and purifying polynucleotides can be used in the preparation of polynucleotide therapeutics of the invention.  
15 For use as a vaccine, a polynucleotide of the invention can be formulated according to various methods.

First, a polynucleotide can be used in a naked form, free of any delivery vehicles, such as anionic liposomes, cationic lipids, microparticles, *e.g.*, gold microparticles, precipitating agents, *e.g.*, calcium phosphate, or any other transfection-facilitating agent. In  
20 this case, the polynucleotide can be simply diluted in a physiologically acceptable solution, such as sterile saline or sterile buffered saline, with or without a carrier. When present, the carrier preferably is isotonic, hypotonic, or weakly hypertonic, and has a relatively low ionic strength, such as provided by a sucrose solution, *e.g.*, a solution containing 20% sucrose.

Alternatively, a polynucleotide can be associated with agents that assist in cellular  
25 uptake. It can be, *i.a.*, (i) complemented with a chemical agent that modifies the cellular permeability, such as bupivacaine (see, *e.g.*, WO 94/16737), (ii) encapsulated into liposomes, or (iii) associated with cationic lipids or silica, gold, or tungsten microparticles.

Anionic and neutral liposomes are well-known in the art (see, *e.g.*, Liposomes: A Practical Approach, RPC New Ed, IRL press (1990), for a detailed description of methods for  
30 making liposomes) and are useful for delivering a large range of products, including polynucleotides.

Cationic lipids are also known in the art and are commonly used for gene delivery. Such lipids include Lipofectin™ also known as DOTMA (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride), DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane), DDAB (dimethyldioctadecylammonium bromide), DOGS (dioctadecylamidoglycyl spermine) and cholesterol derivatives such as DC-Chol (3 beta-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol). A description of these cationic lipids can be found in EP 187,702, WO 90/11092, U.S. Patent No. 5,283,185, WO 91/15501, WO 95/26356, and U.S. Patent No. 5,527,928. Cationic lipids for gene delivery are preferably used in association with a neutral lipid such as DOPE (dioleoyl phosphatidylethanolamine), as, for example, described in WO 90/11092.

Other transfection-facilitating compounds can be added to a formulation containing cationic liposomes. A number of them are described in, *e.g.*, WO 93/18759, WO 93/19768, WO 94/25608, and WO 95/2397. They include, *i.a.*, spermine derivatives useful for facilitating the transport of DNA through the nuclear membrane (see, for example, WO 93/18759) and membrane-permeabilizing compounds such as GALA, Gramicidine S, and cationic bile salts (see, for example, WO 93/19768).

Gold or tungsten microparticles can also be used for gene delivery, as described in WO 91/359, WO 93/17706, and Tang *et al.* (Nature (1992) 356:152). In this case, the microparticle-coated polynucleotides can be injected *via* intradermal or intraepidermal routes using a needleless injection device ("gene gun"), such as those described in U.S. Patent No. 4,945,050, U.S. Patent No. 5,015,580, and WO 94/24263.

The amount of DNA to be used in a vaccine recipient depends, *e.g.*, on the strength of the promoter used in the DNA construct, the immunogenicity of the expressed gene product, the condition of the mammal intended for administration (*e.g.*, the weight, age, and general health of the mammal), the mode of administration, and the type of formulation. In general, a therapeutically or prophylactically effective dose from about 1  $\mu$ g to about 1 mg, preferably, from about 10  $\mu$ g to about 800  $\mu$ g and, more preferably, from about 25  $\mu$ g to about 250  $\mu$ g, can be administered to human adults. The administration can be achieved in a single dose or repeated at intervals.

The route of administration can be any conventional route used in the vaccine field. As general guidance, a polynucleotide of the invention can be administered *via* a mucosal

surface, *e.g.*, an ocular, intranasal, pulmonary, oral, intestinal, rectal, vaginal, and urinary tract surface; or *via* a parenteral route, *e.g.*, by an intravenous, subcutaneous, intraperitoneal, intradermal, intraepidermal, or intramuscular route. The choice of the administration route will depend on, *e.g.*, the formulation that is selected. A polynucleotide formulated in association with bupivacaine is advantageously administered into muscles. When a neutral or anionic liposome or a cationic lipid, such as DOTMA or DC-Chol, is used, the formulation can be advantageously injected *via* intravenous, intranasal (aerosolization), intramuscular, intradermal, and subcutaneous routes. A polynucleotide in a naked form can advantageously be administered *via* the intramuscular, intradermal, or sub-cutaneous routes.

Although not absolutely required, such a composition can also contain an adjuvant. If so, a systemic adjuvant that does not require concomitant administration in order to exhibit an adjuvant effect is preferable such as, *e.g.*, QS21, which is described in U.S. Patent No. 5,057,546.

The sequence information provided in the present application enables the design of specific nucleotide probes and primers that can be useful in diagnosis. Accordingly, in a fifth aspect of the invention, there is provided a nucleotide probe or primer having a sequence found in or derived by degeneracy of the genetic code from a sequence shown in SEQ ID NO:1 to 2.

The term "probe" as used in the present application refers to DNA (preferably single stranded) or RNA molecules (or modifications or combinations thereof) that hybridize under the stringent conditions, as defined above, to nucleic acid molecules having sequences homologous to those shown in SEQ ID NOs:1 and 2, or to a complementary or anti-sense sequence. Generally, probes are significantly shorter than full-length sequences shown in SEQ ID NOs:1 and 2; for example, they can contain from about 5 to about 100, preferably from about 10 to about 80 nucleotides. In particular, probes have sequences that are at least 75%, preferably at least 85%, more preferably 95% homologous to a portion of a sequence as shown in SEQ ID NOs:1 and 2 or that are complementary to such sequences. Probes can contain modified bases such as inosine, methyl-5-deoxycytidine, deoxyuridine, dimethylamino-5-deoxyuridine, or diamino-2, 6-purine. Sugar or phosphate residues can also be modified or substituted. For example, a deoxyribose residue can be replaced by a polyamide (Nielsen *et al.*, Science (1991) 254:1497) and phosphate residues can be replaced by ester groups such as

diphosphate, alkyl, arylphosphonate and phosphorothioate esters. In addition, the 2'-hydroxyl group on ribonucleotides can be modified by including, *e.g.*, alkyl groups.

Probes of the invention can be used in diagnostic tests, as capture or detection probes. Such capture probes can be conventionally immobilized on a solid support, directly or indirectly, by covalent means or by passive adsorption. A detection probe can be labelled by a detection marker selected from radioactive isotopes; enzymes such as peroxidase, alkaline phosphatase, and enzymes able to hydrolyze a chromogenic, fluorogenic, or luminescent substrate; compounds that are chromogenic, fluorogenic, or luminescent; nucleotide base analogs; and biotin.

Probes of the invention can be used in any conventional hybridization technique, such as dot blot (Maniatis *et al.*, Molecular Cloning: A Laboratory Manual (1982) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), Southern blot (Southern, J. Mol. Biol. (1975) 98:503), northern blot (identical to Southern blot to the exception that RNA is used as a target), or the sandwich technique (Dunn *et al.*, Cell (1977) 12:23). The latter technique involves the use of a specific capture probe and/or a specific detection probe with nucleotide sequences that at least partially differ from each other.

A primer is usually a probe of about 10 to about 40 nucleotides that is used to initiate enzymatic polymerization of DNA in an amplification process (*e.g.*, PCR), in an elongation process, or in a reverse transcription method. In a diagnostic method involving PCR, primers can be labelled.

Thus, the invention also encompasses (i) a reagent containing a probe of the invention for detecting and/or identifying the presence of *Chlamydia* in a biological material; (ii) a method for detecting and/or identifying the presence of *Chlamydia* in a biological material, in which (a) a sample is recovered or derived from the biological material, (b) DNA or RNA is extracted from the material and denatured, and (c) exposed to a probe of the invention, for example, a capture, detection probe or both, under stringent hybridization conditions, such that hybridization is detected; and (iii) a method for detecting and/or identifying the presence of *Chlamydia* in a biological material, in which (a) a sample is recovered or derived from the biological material, (b) DNA is extracted therefrom, (c) the extracted DNA is primed with at least one, and preferably two, primers of the invention and amplified by polymerase chain reaction, and (d) the amplified DNA fragment is produced.

As previously mentioned, polypeptides that can be produced upon expression of the newly identified open reading frames are useful vaccine agents.

Therefore, a sixth aspect of the invention features a substantially purified polypeptide or polypeptide derivative having an amino acid sequence encoded by a polynucleotide of the invention.

A "substantially purified polypeptide" is defined as a polypeptide that is separated from the environment in which it naturally occurs and/or that is free of the majority of the polypeptides that are present in the environment in which it was synthesized. For example, a substantially purified polypeptide is free from cytoplasmic polypeptides. Those skilled in the art will understand that the polypeptides of the invention can be purified from a natural source, *i.e.*, a *Chlamydia* strain, or can be produced by recombinant means.

Homologous polypeptides or polypeptide derivatives encoded by polynucleotides of the invention can be screened for specific antigenicity by testing cross-reactivity with an antiserum raised against the polypeptide of reference having an amino acid sequence as shown in SEQ ID NOs:3-4. Briefly, a monospecific hyperimmune antiserum can be raised against a purified reference polypeptide, as such or as a fusion polypeptide, for example, an expression product of MBP, GST, or His-tag systems, or a synthetic peptide predicted to be antigenic. The homologous polypeptide or derivative screened for specific antigenicity can be produced as such or as a fusion polypeptide. In this latter case, and if the antiserum is also raised against a fusion polypeptide, two different fusion systems are employed. Specific antigenicity can be determined according to a number of methods, including Western blot (Towbin *et al.*, Proc. Natl. Acad. Sci. USA (1979) 76:4350), dot blot, and ELISA, as described below.

In a Western blot assay, the product to be screened, either as a purified preparation or a total *E. coli* extract, is submitted to SDS-Page electrophoresis as described by Laemmli (Nature (1970) 227:680). After transfer to a nitrocellulose membrane, the material is further incubated with the monospecific hyperimmune antiserum diluted in the range of dilutions from about 1:5 to about 1:5000, preferably from about 1:100 to about 1:500. Specific antigenicity is shown once a band corresponding to the product exhibits reactivity at any of the dilutions in the above range.

In an ELISA assay, the product to be screened is preferably used as the coating antigen. A purified preparation is preferred, although a whole cell extract can also be used.



Briefly, about 100  $\mu$ l of a preparation at about 10  $\mu$ g protein/ml are distributed into wells of a 96-well polycarbonate ELISA plate. The plate is incubated for 2 hours at 37°C then overnight at 4°C. The plate is washed with phosphate buffer saline (PBS) containing 0.05% Tween 20 (PBS/Tween buffer). The wells are saturated with 250  $\mu$ l PBS containing 1% bovine serum albumin (BSA) to prevent non-specific antibody binding. After 1 hour incubation at 37°C, the plate is washed with PBS/Tween buffer. The antiserum is serially diluted in PBS/Tween buffer containing 0.5% BSA. 100  $\mu$ l of dilutions are added per well. The plate is incubated for 90 minutes at 37°C, washed and evaluated according to standard procedures. For example, a goat anti-rabbit peroxidase conjugate is added to the wells when specific antibodies were raised in rabbits. Incubation is carried out for 90 minutes at 37°C and the plate is washed. The reaction is developed with the appropriate substrate and the reaction is measured by colorimetry (absorbance measured spectrophotometrically). Under the above experimental conditions, a positive reaction is shown by O.D. values greater than a non immune control serum.

In a dot blot assay, a purified product is preferred, although a whole cell extract can also be used. Briefly, a solution of the product at about 100  $\mu$ g/ml is serially two-fold diluted in 50 mM Tris-HCl (pH 7.5). 100  $\mu$ l of each dilution are applied to a nitrocellulose membrane 0.45  $\mu$ m set in a 96-well dot blot apparatus (Biorad). The buffer is removed by applying vacuum to the system. Wells are washed by addition of 50 mM Tris-HCl (pH 7.5) and the membrane is air-dried. The membrane is saturated in blocking buffer (50 mM Tris-HCl (pH 7.5) 0.15 M NaCl, 10 g/L skim milk) and incubated with an antiserum dilution from about 1:50 to about 1:5000, preferably about 1:500. The reaction is revealed according to standard procedures. For example, a goat anti-rabbit peroxidase conjugate is added to the wells when rabbit antibodies are used. Incubation is carried out 90 minutes at 37°C and the blot is washed. The reaction is developed with the appropriate substrate and stopped. The reaction is measured visually by the appearance of a colored spot, *e.g.*, by colorimetry. Under the above experimental conditions, a positive reaction is shown once a colored spot is associated with a dilution of at least about 1:5, preferably of at least about 1:500.

Therapeutic or prophylactic efficacy of a polypeptide or derivative of the invention can be evaluated as described below.

According to a seventh aspect of the invention, there is provided (i) a composition of matter containing a polypeptide of the invention together with a diluent or carrier; in particular, (ii) a pharmaceutical composition containing a therapeutically or prophylactically effective amount of a polypeptide of the invention; (iii) a method for inducing an immune response against *Chlamydia* in a mammal, by administering to the mammal an immunogenically effective amount of a polypeptide of the invention to elicit an immune response, e.g., a protective immune response to *Chlamydia*; and particularly, (iv) a method for preventing and/or treating a *Chlamydia* (e.g., *C. trachomatis*, *C. psittaci*, *C. pneumoniae*, or *C. pecorum*) infection, by administering a prophylactic or therapeutic amount of a polypeptide of the invention to an individual in need. Additionally, the seventh aspect of the invention encompasses the use of a polypeptide of the invention in the preparation of a medicament for preventing and/or treating *Chlamydia* infection.

The immunogenic compositions of the invention can be administered by any conventional route in use in the vaccine field, in particular to a mucosal (e.g., ocular, intranasal, pulmonary, oral, gastric, intestinal, rectal, vaginal, or urinary tract) surface or via the parenteral (e.g., subcutaneous, intradermal, intramuscular, intravenous, or intraperitoneal) route. The choice of the administration route depends upon a number of parameters, such as the adjuvant associated with the polypeptide. For example, if a mucosal adjuvant is used, the intranasal or oral route will be preferred and if a lipid formulation or an aluminum compound is used, the parenteral route will be preferred. In the latter case, the sub-cutaneous or intramuscular route is most preferred. The choice can also depend upon the nature of the vaccine agent. For example, a polypeptide of the invention fused to CTB or LTB will be best administered to a mucosal surface.

A composition of the invention can contain one or several polypeptides or derivatives of the invention. It can also contain at least one additional *Chlamydia* antigen, or a subunit, fragment, homolog, mutant, or derivative thereof.

For use in a composition of the invention, a polypeptide or derivative thereof can be formulated into or with liposomes, preferably neutral or anionic liposomes, microspheres, ISCOMS, or virus-like particles (VLPs) to facilitate delivery and/or enhance the immune response. These compounds are readily available to one skilled in the art; for example, see Liposomes: A Practical Approach (*supra*).

Adjuvants other than liposomes and the like can also be used and are known in the art. A appropriate selection can conventionally be made by those skilled in the art, for example, from the list provided below.

Administration can be achieved in a single dose or repeated as necessary at intervals as can be determined by one skilled in the art. For example, a priming dose can be followed by three booster doses at weekly or monthly intervals. An appropriate dose depends on various parameters including the recipient (*e.g.*, adult or infant), the particular vaccine antigen, the route and frequency of administration, the presence/absence or type of adjuvant, and the desired effect (*e.g.*, protection and/or treatment), as can be determined by one skilled in the art. In general, a vaccine antigen of the invention can be administered by a mucosal route in an amount from about 10  $\mu$ g to about 500 mg, preferably from about 1 mg to about 200 mg. For the parenteral route of administration, the dose usually should not exceed about 1 mg, preferably about 100  $\mu$ g.

When used as vaccine agents, polynucleotides and polypeptides of the invention can be used sequentially as part of a multistep immunization process. For example, a mammal can be initially primed with a vaccine vector of the invention such as a pox virus, *e.g.*, via the parenteral route, and then boosted twice with the polypeptide encoded by the vaccine vector, *e.g.*, via the mucosal route. In another example, liposomes associated with a polypeptide or derivative of the invention can also be used for priming, with boosting being carried out mucosally using a soluble polypeptide or derivative of the invention in combination with a mucosal adjuvant (*e.g.*, LT).

A polypeptide derivative of the invention is also useful as a diagnostic reagent for detecting the presence of anti-*Chlamydia* antibodies, *e.g.*, in a blood sample. Such polypeptides are about 5 to about 80, preferably about 10 to about 50 amino acids in length and can be labeled or unlabeled, depending upon the diagnostic method. Diagnostic methods involving such a reagent are described below.

Upon expression of a DNA molecule of the invention, a polypeptide or polypeptide derivative is produced and can be purified using known laboratory techniques. For example, the polypeptide or polypeptide derivative can be produced as a fusion protein containing a fused tail that facilitates purification. The fusion product can be used to immunize a small mammal, *e.g.*, a mouse or a rabbit, in order to raise antibodies against the polypeptide or

polypeptide derivative (monospecific antibodies). The eighth aspect of the invention thus provides a monospecific antibody that binds to a polypeptide or polypeptide derivative of the invention.

By "monospecific antibody" is meant an antibody that is capable of reacting with a unique naturally-occurring *Chlamydia* polypeptide. An antibody of the invention can be polyclonal or monoclonal. Monospecific antibodies can be recombinant, e.g., chimeric (e.g., constituted by a variable region of murine origin associated with a human constant region), humanized (a human immunoglobulin constant backbone-together-with-hypervariable region of animal, e.g., murine, origin), and/or single chain. Both polyclonal and monospecific antibodies can also be in the form of immunoglobulin fragments, e.g., F(ab)'2 or Fab fragments. The antibodies of the invention can be of any isotype, e.g., IgG or IgA, and polyclonal antibodies can be of a single isotype or can contain a mixture of isotypes.

The antibodies of the invention, which are raised to a polypeptide or polypeptide derivative of the invention, can be produced and identified using standard immunological assays, e.g., Western blot analysis, dot blot assay, or ELISA (see, e.g., Coligan *et al.*, Current Protocols in Immunology (1994) John Wiley & Sons, Inc., New York, NY). The antibodies can be used in diagnostic methods to detect the presence of a *Chlamydia* antigen in a sample, such as a biological sample. The antibodies can also be used in affinity chromatography methods for purifying a polypeptide or polypeptide derivative of the invention. As is discussed further below, such antibodies can be used in prophylactic and therapeutic passive immunization methods.

Accordingly, a ninth aspect of the invention provides (i) a reagent for detecting the presence of *Chlamydia* in a biological sample that contains an antibody, polypeptide, or polypeptide derivative of the invention; and (ii) a diagnostic method for detecting the presence of *Chlamydia* in a biological sample, by contacting the biological sample with an antibody, a polypeptide, or a polypeptide derivative of the invention, such that an immune complex is formed, and by detecting such complex to indicate the presence of *Chlamydia* in the sample or the organism from which the sample is derived.

Those skilled in the art will understand that the immune complex is formed between a component of the sample and the antibody, polypeptide, or polypeptide derivative, whichever is used, and that any unbound material can be removed prior to detecting the

complex. As can be easily understood, a polypeptide reagent is useful for detecting the presence of anti-*Chlamydia* antibodies in a sample, *e.g.*, a blood sample, while an antibody of the invention can be used for screening a sample, such as a gastric extract or biopsy, for the presence of *Chlamydia* polypeptides.

5 For use in diagnostic applications, the reagent (*i.e.*, the antibody, polypeptide, or polypeptide derivative of the invention) can be in a free state or immobilized on a solid support, such as a tube, a bead, or any other conventional support used in the field. Immobilization can be achieved using direct or indirect means. Direct means include passive adsorption (non-covalent binding) or covalent binding between the support and the reagent. 10 By "indirect means" is meant that an anti-reagent compound that interacts with a reagent is first attached to the solid support. For example, if a polypeptide reagent is used, an antibody that binds to it can serve as an anti-reagent, provided that it binds to an epitope that is not involved in the recognition of antibodies in biological samples. Indirect means can also employ a ligand-receptor system, for example, a molecule such as a vitamin can be grafted 15 onto the polypeptide reagent and the corresponding receptor can be immobilized on the solid phase. This is illustrated by the biotin-streptavidin system. Alternatively, indirect means can be used, *e.g.*, by adding to the reagent a peptide tail, chemically or by genetic engineering, and immobilizing the grafted or fused product by passive adsorption or covalent linkage of the peptide tail.

20 According to a tenth aspect of the invention, there is provided a process for purifying, from a biological sample, a polypeptide or polypeptide derivative of the invention, which involves carrying out antibody-based affinity chromatography with the biological sample, wherein the antibody is a monospecific antibody of the invention.

For use in a purification process of the invention, the antibody can be polyclonal or 25 monospecific, and preferably is of the IgG type. Purified IgGs can be prepared from an antiserum using standard methods (see, *e.g.*, Coligan *et al.*, *supra*). Conventional chromatography supports, as well as standard methods for grafting antibodies, are disclosed in, *e.g.*, Antibodies: A Laboratory Manual, D. Lane, E. Harlow, Eds. (1988).

Briefly, a biological sample, such as an *C. pneumoniae* extract, preferably in a 30 buffer solution, is applied to a chromatography material, preferably equilibrated with the buffer used to dilute the biological sample so that the polypeptide or polypeptide derivative of

the invention (*i.e.*, the antigen) is allowed to adsorb onto the material. The chromatography material, such as a gel or a resin coupled to an antibody of the invention, can be in batch form or in a column. The unbound components are washed off and the antigen is then eluted with an appropriate elution buffer, such as a glycine buffer or a buffer containing a chaotropic agent, *e.g.*, guanidine HCl, or high salt concentration (*e.g.*, 3 M MgCl<sub>2</sub>). Eluted fractions are recovered and the presence of the antigen is detected, *e.g.*, by measuring the absorbance at 280 nm.

An antibody of the invention can be screened for therapeutic efficacy as described as follows. According to an eleventh aspect of the invention, there is provided (i) a composition of matter containing a monospecific antibody of the invention, together with a diluent or carrier; (ii) a pharmaceutical composition containing a therapeutically or prophylactically effective amount of a monospecific antibody of the invention, and (iii) a method for treating or preventing a *Chlamydia* (*e.g.*, *C. trachomatis*, *C. psittaci*, *C. pneumoniae* or *C. pecorum*) infection, by administering a therapeutic or prophylactic amount of a monospecific antibody of the invention to an individual in need. Additionally, the eleventh aspect of the invention encompasses the use of a monospecific antibody of the invention in the preparation of a medicament for treating or preventing *Chlamydia* infection.

To this end, the monospecific antibody can be polyclonal or monoclonal, preferably of the IgA isotype (predominantly). In passive immunization, the antibody can be administered to a mucosal surface of a mammal, *e.g.*, the gastric mucosa, *e.g.*, orally or intragastrically, advantageously, in the presence of a bicarbonate buffer. Alternatively, systemic administration, not requiring a bicarbonate buffer, can be carried out. A monospecific antibody of the invention can be administered as a single active component or as a mixture with at least one monospecific antibody specific for a different *Chlamydia* polypeptide. The amount of antibody and the particular regimen used can be readily determined by one skilled in the art. For example, daily administration of about 100 to 1,000 mg of antibodies over one week, or three doses per day of about 100 to 1,000 mg of antibodies over two or three days, can be an effective regimens for most purposes.

Therapeutic or prophylactic efficacy can be evaluated using standard methods in the art, *e.g.*, by measuring induction of a mucosal immune response or induction of protective and/or therapeutic immunity, using, *e.g.*, the *C. pneumoniae* mouse model. Those skilled in

the art will recognize that the *C. pneumoniae* strain of the model can be replaced with another *Chlamydia* strain. For example, the efficacy of DNA molecules and polypeptides from *C. pneumoniae* is preferably evaluated in a mouse model using an *C. pneumoniae* strain. Protection can be determined by comparing the degree of *Chlamydia* infection to that of a control group. Protection is shown when infection is reduced by comparison to the control group. Such an evaluation can be made for polynucleotides, vaccine vectors, polypeptides and derivatives thereof, as well as antibodies of the invention.

Adjuvants useful in any of the vaccine compositions described above are as follows.

Adjuvants for parenteral administration include aluminum compounds, such as aluminum hydroxide, aluminum phosphate, and aluminum hydroxy phosphate. The antigen can be precipitated with, or adsorbed onto, the aluminum compound according to standard protocols. Other adjuvants, such as RIBI (ImmunoChem, Hamilton, MT), can be used in parenteral administration.

Adjuvants for mucosal administration include bacterial toxins, *e.g.*, the cholera toxin (CT), the *E. coli* heat-labile toxin (LT), the *Clostridium difficile* toxin A and the pertussis toxin (PT), or combinations, subunits, toxoids, or mutants thereof. For example, a purified preparation of native cholera toxin subunit B (CTB) can be of use. Fragments, homologs, derivatives, and fusions to any of these toxins are also suitable, provided that they retain adjuvant activity. Preferably, a mutant having reduced toxicity is used. Suitable mutants are described, *e.g.*, in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627 (Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PT mutant). Additional LT mutants that can be used in the methods and compositions of the invention include, *e.g.*, Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other adjuvants, such as a bacterial monophosphoryl lipid A (MPLA) of, *e.g.*, *E. coli*, *Salmonella minnesota*, *Salmonella typhimurium*, or *Shigella flexneri*; saponins, or polylactide glycolide (PLGA) microspheres, can also be used in mucosal administration.

Adjuvants useful for both mucosal and parenteral administrations include polyphosphazene (WO 95/2415), DC-chol (3 b-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol; U.S. Patent No. 5,283,185 and WO 96/14831) and QS-21 (WO 88/9336).

Any pharmaceutical composition of the invention, containing a polynucleotide, a polypeptide, a polypeptide derivative, or an antibody of the invention, can be manufactured in a conventional manner. In particular, it can be formulated with a pharmaceutically acceptable diluent or carrier, *e.g.*, water or a saline solution such as phosphate buffer saline. In general, a diluent or carrier can be selected on the basis of the mode and route of administration, and standard pharmaceutical practice. Suitable pharmaceutical carriers or diluents, as well as pharmaceutical necessities for their use in pharmaceutical formulations, are described in *Remington's Pharmaceutical Sciences*, a standard reference text in this field and in the USP/NF.

The invention also includes methods in which *Chlamydia* infection, are treated by oral administration of a *Chlamydia* polypeptide of the invention and a mucosal adjuvant, in combination with an antibiotic, an antacid, sucralfate, or a combination thereof. Examples of such compounds that can be administered with the vaccine antigen and the adjuvant are antibiotics, including, *e.g.*, macrolides, tetracyclines, and derivatives thereof (specific examples of antibiotics that can be used include azithromycin or doxycyclin or immunomodulators such as cytokines or steroids. In addition, compounds containing more than one of the above-listed components coupled together, can be used. The invention also includes compositions for carrying out these methods, *i.e.*, compositions containing a *Chlamydia* antigen (or antigens) of the invention, an adjuvant, and one or more of the above-listed compounds, in a pharmaceutically acceptable carrier or diluent.

Amounts of the above-listed compounds used in the methods and compositions of the invention can readily be determined by one skilled in the art. In addition, one skilled in the art can readily design treatment/immunization schedules. For example, the non-vaccine components can be administered on days 1-14, and the vaccine antigen + adjuvant can be administered on days 7, 14, 21, and 28.



# **REFERENCES**

1. Grayston et al. (1995) Journal of Infectious Diseases 168:1231
2. Campos et al. (1995) Investigation of Ophthalmology and Visual Science 36:1477
3. Grayston et al (1990) Journal of Infectious Diseases 161:618
- 5 4. Marrie (1993) Clinical Infectious Diseases. 18:501
5. Wang et al (1986) Chlamydial infections. Cambridge University Press, Cambridge. p. 329
6. Saikku et al.(1988) Lancet;ii:983
7. Thom et al. (1992) JAMA 268:68
8. Linnanmaki et al. (1993), Circulation 87:1030
- 10 9. Saikku et al. (1992)Annals Internal Medicine 116:273
10. Melnick et al(1993) American Journal of Medicine 95:499
- 11 Shor et al. (1992) South African. Medical Journal 82:158
12. Kuo et al. (1993) Journal of Infectious Diseases 167:841
13. Kuo et al. (1993) Arteriosclerosis and Thrombosis 13:1500
- 15 14. Campbell et al (1995) Journal of Infectious Diseases 172:585
15. Chiu et al. Circulation, 1997 (In Press).
16. Ramirez et al (1996) Annals of Internal Medicine 125:979
17. Jackson et al. Abst. K121, p272, 36th ICAAC, 15-18 Sept. 1996, New Orleans.
18. Fong et al (1997) Journal of Clinical Microbiology 35:48

---

- 20 19. Hahn DL, et al. Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma.  
Ann Allergy Asthma Immunol. 1998 Jan; 80(1): 45-49.
20. Hahn DL, et al. Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma. Epidemiol Infect. 1996 Dec; 117(3): 513-517.
- 25 21. Bjornsson E, et al. Serology of chlamydia in relation to asthma and bronchial hyperresponsiveness. Scand J Infect Dis. 1996; 28(1): 63-69.
22. Hahn DL. Treatment of *Chlamydia pneumoniae* infection in adult asthma: a before-after trial. J Fam Pract. 1995 Oct; 41(4): 345-351.
23. Allegra L, et al. Acute exacerbations of asthma in adults: role of Chlamydia pneumoniae infection. Eur Respir J. 1994 Dec; 7(12): 2165-2168.
- 30

24. Hahn DL, et al. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA. 1991 Jul 10; 266(2): 225-230.
25. Pal et al. (1996) Infection and Immunity. 64:5341
- 5 26. Jones et al. (1995) Vaccine 13:715
27. Igiertsemes et al. (1993) Immunology 5:317
28. Igiertseme et al (1993) Regional Immunology 5:317
29. Magee et al (1993) Regional Immunology 5: 305
30. Landers et al (1991) Infection & Immunity 59:3774
- 10 31. Magee et al (1995) Infection & Immunity 63:516
32. Cotter et al. (1995) Infection and Immunity 63:4704
33. Campbell et al (1990) Infection and Immunity 58:93
34. McCafferty et al (1995) Infection and Immunity 63:2387-9.
35. Knudsen et al (1996) Third Meeting of the European Society for Chlamydia Research, Vienna
- 15 36. Wiedmann-Al-Ahmad, M, et al. Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein of Chlamydia pneumoniae. Clin Diagn Lab Immunol. 1997 Nov; 4(6): 700-704
37. Hughes et al., 1992. Infect. Immun. 60(9):3497.
38. Dion et al., 1990. Virology 179:474-477.
- 20 39. Snijders et al., 1991. J. Gen. Virol. 72:557-565.
40. Langeveld et al., Vaccine 12(15):1473-1480, 1994
41. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons Inc., 1994
42. Kunkel et al. Proc. Natl. Acad. Sci. USA (1985) 82:448
43. Silhavy et al. Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press,
- 25 1984
44. Davis et al. A Manual for Genetic Engineering: Advanced Bacterial Genetics, Cold Spring Harbor Laboratory Press, 1980)
45. Casey & Davidson, Nucl. Acid Res. (1977) 4:1539
46. Cagnon et al., Protein Engineering (1991) 4(7):843
- 30 47. Takase et al., J. Bact. (1987) 169:5692

Figure 1 CPN100626 Coding sequence

tcctgaactc cactcgaaat tactgattag ccaaggtacg tggacgacgc aggccactcc 60  
 tgtgacctac aatgctttag ggatcaaagt gaaaaatacc atgcaggtgt ttcctaaagt 120  
 cactctctcc ttagattact ctgcgatat ttcttcctcc acgctgagtc actacttaa 180  
 cgtggcgagt agaattgagt ttttaacaat aagtgaccaa aacagaaaga ttaaggaacc 240  
 tctagtgtca aagactctct ctaagttttt attctatctc gggaatttca cagcctgcac 300  
 gttcgggatg actcctgcag tgtatagttt acaaacggac tcccttgaaa agtttgcttt 360  
 agagagggat gaagagtttc gtacgagctt tcctctctta gactctctct ccactcttac 420  
 aggattttct ccaataacta cgtttgttgg aaatagacat aattcctctc aagacattgt 480  
 actttctaac tacaagtcta ttgataacat cctctctctt tggacatcgg ctgggggagc 540  
 tgtgtcctgt aataatttct tattatcaaa tgttgaagac catgccttct tcagtaaaaa 600  
 tctcgcgagt gggactggag gcgcgattgc ttgccaggga gcctgcacaa tcacgaagaa 660  
 tagaggaccc cttatttttt tcagcaatcg aggtcttaac aatgcgagta caggaggaga 720  
 aactcgtggg ggtgcgattg cctgtaatgg agacttcacg atttctcaaa atcaaggagc 780  
 tttctacttt gtcaacaatt ccgtcaacaa ctggggagga gccctctcca ccaatggaca 840  
 ctgccgcatc caaagcaaca gggcacctct actctttttt aacaatacag cccctagtgg 900  
 aggggggtgc cttcgtagtg aaaatacaac gatctctgat aacacgcgtc ctattttatt 960  
 taagaacaac tgtgggaaca atggcggggg cattcaacaa agcgttactg ttgcgataaa 1020  
 aaataactcc gggtcgggtg ttttcaataa caacacagcg ttatctgggt cgataaattc 1080  
 aggaaatggt tcaggagggg cgatttatac aacaaacctt tccatagacg ataaccctgg 1140  
 aactattctt ttcaataata actactgcat tcgcgatggc ggagctatct gtacacaatt 1200  
 tttgacaatc aaaaatagtg gccacgtata tttcaccaac aatcaaggaa actggggagg 1260  
 tgctcttatg ctctacaggg acagcacctg cctactcttc gcggaacaag gaaatatcgc 1320  
 atttcaaaat aatgaggttt tcctcaccac atttggtaga tacaacgcca tacattgtac 1380  
 accaaatagc aacttacaac ttggagctaa taaggggtat acgactgctt tttttgatcc 1440  
 tatagaacac caacatccaa ctacaaatcc tctaattctt aatcccaatg cgaaccatca 1500  
 gggaacgatc ttattttctt cagcctatat cccagaagct tctgactacg aaaataattt 1560  
 cattagcagc tcgaaaaata cctctgaact togcaatggt gtctctctta tcgaggatcg 1620  
 tgcgggatgg caattctata agttcactca aaaaggaggt atccttaa at tagggcatgc 1680  
 ggcgagtatt gcaacaactg ccaactctga gactccatca actagttag getcccaggt 1740  
 catcattaat aaccttgcca ttaacctccc ctcgatctta gcaaaaggaa aagctcctac 1800  
 cttgttgatc cgtcctctac aatctagtgc tcctttcaca gaggacaata accctacaat 1860  
 tactttatca ggtcctctga cactcttaaa tgaggaaaac cgcatccct acgacagtat 1920  
 agatctctct gagcctttac aaaacattca tcttctttct ttatcggtat taacagcacg 1980  
 tcatatcaat accgataact ttcactctga aagcttaaat gcgactgagc attacggtta 2040  
 tcaaggcatc tgggtctcctt attgggtaga gacgataaca acaacaata aegettetat 2100  
 agagacggca aacacccctt acagagctct gtatgccaat tggactccct taggatataa 2160  
 ggtcaatcct gaataccaag gagatcttgc tacgactccc ctatggcaat cctttcatac 2220  
 tatgttctct ctattaagaa gttataatcg aactggtgat tctgatatcg agaggccttt 2280  
 cttagaaatt caagggattg ccgacggcct ctttgttcat caaaatagca tccccggggc 2340  
 tccaggattc cgtatccaat ctacagggta ttccttaca gcatcctccg aaacttcttt 2400  
 acatcagaaa atctccttag gttttgcaca gttcttcacc cgactaaag aaatcggatc 2460  
 aagcaacaac gtctcggctc acaatacagt ctcttcaact tatgttgagc ttccgtggtt 2520  
 ccaagaggcc tttgcaacat cccacagttt agogtatggc tatggggacc atcacctcca 2580  
 cgcctacatc cgtcacatca agaacagggc agaagggacg tgttatagcc atacattagc 2640  
 agcagctatc ggctgttctt tcccttgcca acagaaatcc tatcttcacc tcagcccgtt 2700  
 cgttcaggca attgcaatac gttctcacca aacagcgttc gaagagattg gtgacaatcc 2760  
 ccgaaagtgt gtctctcaaa agcctttcta taatctgacc ttacctctag gaatccaagg 2820  
 aaaatggcag tcaaaaattcc acgtacctac agaattggact ctagaacttt cttaccaacc 2880  
 ggtactctat caacaaaatc cccaaatcgg tgtcacgcta cttgcgagcg gaggttctctg 2940  
 ggatatccta ggccataact atgttcgcaa tgcttttaggg tacaagtcc acaatcaaac 3000  
 tgcgctcttc cgttctctcg atctattctt ggattacca ggtatcggtc cctcctcgac 3060  
 atctacgcac catctccaag caggaagtac cttaaaatc taaaataaaa gaacgataaa 3120  
 attgaaatct ttagaattaa caactatccg atgagctacg ttagcccaat cggtagagga 3180  
 ctccctcaaa atttaataaa

Figure 2 CPN100626 Deduced Protein sequence

Met Gln Val Phe Pro Lys Val Thr Leu Ser Leu Asp Tyr Ser Ala Asp  
 1 5 10 15  
 Ile Ser Ser Ser Thr Leu Ser His Tyr Leu Asn Val Ala Ser Arg Met  
 20 25 30  
 Arg Phe Leu Thr Ile Ser Asp Gln Asn Arg Lys Ile Lys Glu Pro Leu  
 35 40 45  
 Val Ser Lys Thr Pro Pro Lys Phe Leu Phe Tyr Leu Gly Asn Phe Thr  
 50 55 60  
 Ala Cys Met Phe Gly Met Thr Pro Ala Val Tyr Ser Leu Gln Thr Asp  
 65 70 75 80  
 Ser Leu Glu Lys Phe Ala Leu Glu Arg Asp Glu Glu Phe Arg Thr Ser  
 85 90 95  
 Phe Pro Leu Leu Asp Ser Leu Ser Thr Leu Thr Gly Phe Ser Pro Ile  
 100 105 110  
 Thr Thr Phe Val Gly Asn Arg His Asn Ser Ser Gln Asp Ile Val Leu  
 115 120 125  
 Ser Asn Tyr Lys Ser Ile Asp Asn Ile Leu Leu Leu Trp Thr Ser Ala  
 130 135 140  
 Gly Gly Ala Val Ser Cys Asn Asn Phe Leu Leu Ser Asn Val Glu Asp  
 145 150 155 160  
 His Ala Phe Phe Ser Lys Asn Leu Ala Ile Gly Thr Gly Gly Ala Ile  
 165 170 175  
 Ala Cys Gln Gly Ala Cys Thr Ile Thr Lys Asn Arg Gly Pro Leu Ile  
 180 185 190  
 Phe Phe Ser Asn Arg Gly Leu Asn Asn Ala Ser Thr Gly Gly Glu Thr  
 195 200 205  
 Arg Gly Gly Ala Ile Ala Cys Asn Gly Asp Phe Thr Ile Ser Gln Asn  
 210 215 220  
 Gln Gly Thr Phe Tyr Phe Val Asn Asn Ser Val Asn Asn Trp Gly Gly  
 225 230 235 240  
 Ala Leu Ser Thr Asn Gly His Cys Arg Ile Gln Ser Asn Arg Ala Pro  
 245 250 255  
 Leu Leu Phe Phe Asn Asn Thr Ala Pro Ser Gly Gly Gly Ala Leu Arg  
 260 265 270  
 Ser Glu Asn Thr Thr Ile Ser Asp Asn Thr Arg Pro Ile Tyr Phe Lys  
 275 280 285  
 Asn Asn Cys Gly Asn Asn Gly Gly Ala Ile Gln Thr Ser Val Thr Val  
 290 295 300  
 Ala Ile Lys Asn Asn Ser Gly Ser Val Ile Phe Asn Asn Asn Thr Ala  
 305 310 315 320  
 Leu Ser Gly Ser Ile Asn Ser Gly Asn Gly Ser Gly Gly Ala Ile Tyr

325                      330                      335  
 Thr Thr Asn Leu Ser Ile Asp Asp Asn Pro Gly Thr Ile Leu Phe Asn  
                                  340                      345                      350  
 Asn Asn Tyr Cys Ile Arg Asp Gly Gly Ala Ile Cys Thr Gln Phe Leu  
                                  355                      360                      365  
 Thr Ile Lys Asn Ser Gly His Val Tyr Phe Thr Asn Asn Gln Gly Asn  
                                  370                      375                      380  
 Trp Gly Gly Ala Leu Met Leu Leu Gln Asp Ser Thr Cys Leu Leu Phe  
                                  385                      390                      395                      400  
 Ala Glu Gln Gly Asn Ile Ala Phe Gln Asn Asn Glu Val Phe Leu Thr  
                                  405                      410                      415  
 Thr Phe Gly Arg Tyr Asn Ala Ile His Cys Thr Pro Asn Ser Asn Leu  
                                  420                      425                      430  
 Gln Leu Gly Ala Asn Lys Gly Tyr Thr Thr Ala Phe Phe Asp Pro Ile  
                                  435                      440                      445  
 Glu His Gln His Pro Thr Thr Asn Pro Leu Ile Phe Asn Pro Asn Ala  
                                  450                      455                      460  
 Asn His Gln Gly Thr Ile Leu Phe Ser Ser Ala Tyr Ile Pro Glu Ala  
                                  465                      470                      475                      480  
 Ser Asp Tyr Glu Asn Asn Phe Ile Ser Ser Ser Lys Asn Thr Ser Glu  
                                  485                      490                      495  
 Leu Arg Asn Gly Val Leu Ser Ile Glu Asp Arg Ala Gly Trp Gln Phe  
                                  500                      505                      510  
 Tyr Lys Phe Thr Gln Lys Gly Gly Ile Leu Lys Leu Gly His Ala Ala  
                                  515                      520                      525  


---

 Ser Ile Ala Thr Thr Ala Asn Ser Glu Thr Pro Ser Thr Ser Val Gly  
                                  530                      535                      540  
 Ser Gln Val Ile Ile Asn Asn Leu Ala Ile Asn Leu Pro Ser Ile Leu  
                                  545                      550                      555                      560  
 Ala Lys Gly Lys Ala Pro Thr Leu Trp Ile Arg Pro Leu Gln Ser Ser  
                                  565                      570                      575  
 Ala Pro Phe Thr Glu Asp Asn Asn Pro Thr Ile Thr Leu Ser Gly Pro  
                                  580                      585                      590  
 Leu Thr Leu Leu Asn Glu Glu Asn Arg Asp Pro Tyr Asp Ser Ile Asp  
                                  595                      600                      605  
 Leu Ser Glu Pro Leu Gln Asn Ile His Leu Leu Ser Leu Ser Asp Val  
                                  610                      615                      620  
 Thr Ala Arg His Ile Asn Thr Asp Asn Phe His Pro Glu Ser Leu Asn  
                                  625                      630                      635                      640  
 Ala Thr Glu His Tyr Gly Tyr Gln Gly Ile Trp Ser Pro Tyr Trp Val  
                                  645                      650                      655  
 Glu Thr Ile Thr Thr Thr Asn Asn Ala Ser Ile Glu Thr Ala Asn Thr  
                                  660                      665                      670


Leu Tyr Arg Ala Leu Tyr Ala Asn Trp Thr Pro Leu Gly Tyr Lys Val  
 675 680 685  
 Asn Pro Glu Tyr Gln Gly Asp Leu Ala Thr Thr Pro Leu Trp Gln Ser  
 690 695 700  
 Phe His Thr Met Phe Ser Leu Leu Arg Ser Tyr Asn Arg Thr Gly Asp  
 705 710 715 720  
 Ser Asp Ile Glu Arg Pro Phe Leu Glu Ile Gln Gly Ile Ala Asp Gly  
 725 730 735  
 Leu Phe Val His Gln Asn Ser Ile Pro Gly Ala Pro Gly Phe Arg Ile  
 740 745 750  
 Gln Ser Thr Gly Tyr Ser Leu Gln Ala Ser Ser Glu Thr Ser Leu His  
 755 760 765  
 Gln Lys Ile Ser Leu Gly Phe Ala Gln Phe Phe Thr Arg Thr Lys Glu  
 770 775 780  
 Ile Gly Ser Ser Asn Asn Val Ser Ala His Asn Thr Val Ser Ser Leu  
 785 790 795 800  
 Tyr Val Glu Leu Pro Trp Phe Gln Glu Ala Phe Ala Thr Ser His Ser  
 805 810 815  
 Leu Ala Tyr Gly Tyr Gly Asp His His Leu His Ala Tyr Ile Arg His  
 820 825 830  
 Ile Lys Asn Arg Ala Glu Gly Thr Cys Tyr Ser His Thr Leu Ala Ala  
 835 840 845  
 Ala Ile Gly Cys Ser Phe Pro Trp Gln Gln Lys Ser Tyr Leu His Leu  
 850 855 860  


---

 Ser Pro Phe Val Gln Ala Ile Ala Ile Arg Ser His Gln Thr Ala Phe  
 865 870 875 880  
 Glu Glu Ile Gly Asp Asn Pro Arg Lys Phe Val Ser Gln Lys Pro Phe  
 885 890 895  
 Tyr Asn Leu Thr Leu Pro Leu Gly Ile Gln Gly Lys Trp Gln Ser Lys  
 900 905 910  
 Phe His Val Pro Thr Glu Trp Thr Leu Glu Leu Ser Tyr Gln Pro Val  
 915 920 925  
 Leu Tyr Gln Gln Asn Pro Gln Ile Gly Val Thr Leu Leu Ala Ser Gly  
 930 935 940  
 Gly Ser Trp Asp Ile Leu Gly His Asn Tyr Val Arg Asn Ala Leu Gly  
 945 950 955 960  
 Tyr Lys Val His Asn Gln Thr Ala Leu Phe Arg Ser Leu Asp Leu Phe  
 965 970 975  
 Leu Asp Tyr Gln Gly Ser Val Ser Ser Ser Thr Ser Thr His His Leu  
 980 985 990  
 Gln Ala Gly Ser Thr Leu Lys Phe  
 995 1000

Figure 3

## Restriction enzyme analysis of CPN100626



										MnlI									
										Hpy178III									
										CviRI									
										Cac8I									
										CviJI									
										NlaIV									
										BpmI									
										ScrFI									
										BsaJI									
										EcoRI									
										Cac8I									
										CjePI									
										BsgI									
Hpy178III										BsmFI									
NruI										Tth111I									
ThaI										MnlI									



601 TCTCGCGATTGGGACTGGAGGCGCGATTGCTTGCCAGGGAGCCTGCACAATCAGGAAGAA  
 -----+-----+-----+-----+-----+-----+ 660  
 AGAGCGCTAACCCCTGACCTCCGCGCTAACGAACGGTCCCTCGGACGTGTTAGTGCTTCTT

MboII  
 NlaIV  
 AvaII |  
 EcoO109I |  
 Psp5II |  
 Sau96I |  
 SimI |  
 MnlI TaqI MseI RsaI  
 MnlI |  
 TatI |  
 TAGAGGACCCCTTATTTTTTTTTCAGCAATCGAGGTCTTAACAATGCGAGTACAGGAGGAGA  
 661 -----+-----+-----+-----+-----+ 720  
 ATCTCCTGGGGAATAAAAAAAGTCGTTAGCTCCAGAATTGTTACGCTCATGTCCTCCTCT

BssSI BseRI BsmAI Hpy178III  
 |  
 AACTCGTGGGGGTGCGATTGCCTGTAATGGAGACTTCACGATTTCTCAAAATCAAGGGAC  
 721 -----+-----+-----+-----+-----+ 780  
 TTGAGCACCCCCACGCTAACGGACATTACCTCTGAAGTGCTAAAGAGTTTtagttccctg

BanII  
 Bsp1286I  
 BsrI  
 Tsp509I BmrI CviJI FokI  
 HincII MnlI Hin4I MnlI  
 BsmFI HincII NlaIV BseRI BplI  
 TTTCTACTTTGTCAACAATTCCGTCAACAACACTGGGGAGGAGCCCTCTCCACCAATGGACA  
 781 -----+-----+-----+-----+-----+ 840  
 AAAGATGAAACAGTTGTTAAGGCAGTTGTTGACCCCTCCTCGGGAGAGGTGGTTACCTGT

TspRI Bsp1286I BslI  
 AciI NlaIV EcoNI  
 Fnu4HI BmgI BfaI  
 TauI SfaNI BseSI MseI MnlI  
 BtsI MwoI BanI MnlI CviJI  
 CTGCCGCATCCAAAGCAACAGGGCACCTCTACTCTTTTTTAACAATACAGCCCTAGTGG  
 841 -----+-----+-----+-----+-----+ 900  
 GACGGCGTAGGTTTCGTTGTCCCGTGGAGATGAGAAAAAATTGTTATGTCGGGGATCACC

Hpy188IX  
 HgaI  
 Pfl1108I DpnI AflIII  
 HhaI Sau3AI MluI CjePI MseI  
 AGGGGGTGGCTTCGTAGTGAAAATACAACGATCTCTGATAACACGCGTCCTATTTATTT  
 901 -----+-----+-----+-----+-----+ 960  
 TCCCCACGCGAAGCATCACTTTTATGTTGCTAGAGACTATTGTGCGCAGGATAAATAAA

CviJI  
 HaeIII  
 CjePI  
 NlaIV  
 FauI  
 Sth132I Sau96I Tth111II

[illegible][illegible]

BsiHKAI  
 Bsp1286I  
 SfiI  
 MboI  
 AarI  
 AlwNI  
 BspMI  
 AciI  
 EarI  
 ThaI

TGCTCTTATGCTCCTACAGGACAGCACCTGCCTACTCTTCGCGGAACAAGGAAATATCGC

1261 -----+-----+-----+-----+-----+ 1320  
 ACGAGAATACGAGGATGTCCTGTCGTGGACGGATGAGAAGCGCCTTGTTTCCTTTATAGCG

MnlI                      CjeI                      MnlI                      CjeI                      RsaI  
                          CjeI                      HgiEII                      CjeI                      BsrGI  
                          HphI                                                                CjeI                      TatI  
                          |                      |                      |                      |                      |

1321 -----+-----+-----+-----+-----+ 1380  
 ATTTCAAATAATGAGGTTTTCCTCACCACATTGTTAGATACAACGCCATACATTGTAC  
 TAAAGTTTTATTACTCCAAAAGGAGTGGTGTAACCATCTATGTTGCGGTATGTAACATG

                         CjeI                      AluI                      Bst217I                      Sau3AI                      FokI  
                                               CviJI                      AccI                      AlwI                      SfcI  
                                               |                      |                      |                      |                      |

1381 -----+-----+-----+-----+-----+ 1440  
 ACCAAATAGCAACTTACAACCTTGGAGCTAATAAGGGGTATACGACTGCTTTTTTGTATCC  
 TGGTTTATCGTTGAATGTTGAACCTCGATTATTCCTCATATGCTGACGAAAAAACTAGG

                                              MneI                      BccI  
                                               MnlI                                           DrdII  
                                               MseI                                           |

1441 -----+-----+-----+-----+-----+ 1500  
 TATAGAACACCAACATCCAACCTACAAATCCTCTAATCTTTAATCCCAATGCGAACCATCA  
 ATATCTTGTGGTTGTAGGTTGATGTTTAGGAGATTAGAAATTAGGGTTACGCTTGGTAGT

                         MboII                      Hpy188IX                      Pfl1108I  
                          DpnI                      AluI                                           |  
                          Sau3AI                      CviJI                                           |

1501 -----+-----+-----+-----+-----+ 1560  
 GGGAACGATCTTATTTTCTTCAGCCTATATCCCAGAAGCTTCTGACTACGAAAATAATTT  
 CCCTTGCTAGAATAAAAGAAGTCGGATATAGGGTCTTCGAAGACTGATGCTTTTATTAA

                         TaqI                      DpnI                      FauI  
                          AluI                                           Sau3AI  
                          CviJI                      Hpy188IX                      Sth132I  
                          Fnu4HI                      AceIII                      MnlI  
                          TseI                      BbvI                      MnlI                      BcgI                      BsrDI                      MnlI                      TaqI

1561 -----+-----+-----+-----+-----+ 1620  
 CATTAGCAGCTCGAAAAATACCTCTGAACCTTCGCAATGGTGTCTCTATCGAGGATCG  
 GTAATCGTCGAGCTTTTTTATGGAGACTTGAAGCGTTACCACAGGAGAGATAGCTCCTAGC

                                              Fnu4HI                      TauI  
                                                                    AciI  
                                                                    NlaIII  
                          AlwI                      Tsp509I                      FokI                      BciVI                      NspI  
                          AciI                      BccI                      BcgI                      MnlI                      Tsp509I                      SphI  
                                               |                      |                      |                      |                      |                      |

                         TGCGGGATGGCAATTCTATAAGTTCACTCAAAAAGGAGGTATCCTTAAATTAGGGCATGC

1621 -----+-----+-----+-----+-----+ 1680  
ACGCCCTACCGTTAAGATATTCAAGTGAGTTTTTCCTCCATAGGAATTTAATCCCGTACG

BccI  
Hin4I  
HinfI  
BseMII DdeI  
BstAPI Hpy188IX  
CviRI PleI BfaI NlaIV  
MwoI MwoI BsmAI SpeI CviJI

GGCGAGTATTGCAACAAGTGGCAACTCTGAGACTCCATCAACTAGTGTAGGCTCCAGGT  
1681 -----+-----+-----+-----+-----+ 1740  
CCGCTCATAACGTTGTGTGACGGTTGAGACTCTGAGGTAGTTGATCAGATCCGAGGGTCCA

MnlI  
DdeI  
DpnI  
MnlI  
MseI Sau3AI AluI  
VspI MseI TaqI CviJI

CATCATTAAATAACCTTGCGATTAACTCCCTCGATCTTAGCAAAAGGAAAAGCTCCTAC  
1741 -----+-----+-----+-----+-----+ 1800  
GTAGTAATTATTGGAACGCTAATTGGAGGGGAGCTAGAATCGTTTTCTTTTCGAGGATG

AluI  
Hin4I  
DpnI  
NlaIV  
BamHI  
BstYI  
Sau3AI  
AluI MnlI Tsp509I

CTTCTGGATCCGCTGCTCTAGAACTAGTGGTCTTTTACAGAGAGGACAATAAGCCTAGCAAT  
1801 -----+-----+-----+-----+-----+ 1860  
GAACAGCTAGGAGGAGATGTTAGATCACCAGGAAAGTGTCTCTCTGTTATGGGATGTTA

Hpy188IX Pfl1108I  
AvaII DpnI  
EcoO109I Sau3AI  
Psp5II MseI  
Sau96I MnlI  
Sse8647I MnlI AluI BseMII  
TAAI

TACTTTATCAGGTCCTCTGACACTCTTAAATGAGGAAAACCGCGATCCCTACGACAGTAT  
1861 -----+-----+-----+-----+-----+ 1920  
ATGAAATAGTCCAGGAGACTGTGAGAATTTACTCCTTTTGGCGCTAGGGATGCTGTCATA

CviJI  
DdeI  
Hpy188IX  
DpnI  
BglII  
BstYI  
Sau3AI  
MaeIII  
Hpy188IX  
FokI  
MaeII

AGATCTCTCTGAGGCTTTAGCAACAATTCATCTCTCTTTTATCGGATCTAACAGCAGC  
1921 -----+-----+-----+-----+-----+ 1980

TCTAGAGAGACTCGGAATGTTTTGTAAGTAGAAGAAAGAAATAGCCTACATTGTCGTGC

BseMII  
MseI  
AluI  
CviJI  
HindIII  
FokI      Hpy178III      DdeI      TaaI

1981 TCATATCAATACCGATAACTTTTCATCCTGAAAGCTTAAATGCGACTGAGCATTACGGTTA 2040  
AGTATAGTTATGGCTATTGAAAGTAGGACTTTTGAATTTACGCTGACTCGTAATGCCAAT

BsmAI  
BsaI      SfiI  
BsmAI      BsmAI  
SfaNI      BsmBI

2041 TCAAGGCATCTGGTCTCCTTATTGGGTAGAGACGATAACAACAACAAATAACGCTTCTAT 2100  
AGTTCCGTAGACCAGAGGAATAACCCATCTCTGCTATTGTTGTTGTTTATTGCGAAGATA

BanII  
BsiHKAI  
Bsp1286I  
CjePI  
SacI  
AluI  
CviJI  
MnlI      MunI  
Tth111III      PleI  
BceFI      Tsp509I      Bsu36I      HaeIV  
SfiI      MwoI      HinfI      DdeI      HinfI

2101 AGAGACGGCAAACACCCCTCTACAGAGCTCTGTATGCCAATTGGACTCCCTTAGGATATAA 2160  
TCTCTGCCGTTTGTGGGAGATGTCTCGAGACATACGGTTAACCTGAGGGAATCCTATATT

DpnI  
BglII  
BstYI  
Sau3AI      HinfI  
Hpy178III      BsaJI      Pfl1108I  
CjePI      StyI      PleI

2161 GGTCAATCCTGAATACCAAGGAGATCTTGCTACGACTCCCTATGGCAATCCTTTCATAC 2220  
CCAGTTAGGACTTATGGTTCCTCTAGAACGATGCTGAGGGGATACCGTTAGGAAAGTATG

CviJI  
HaeI  
HaeIII  
Hpy178III  
TaqI  
HphI  
EcoRV  
MnlI  
Hpy188IX  
HinfI  
TfiI  
BsrI      StuI  
MseI      TaqI

2221 TATGTTCTCTCTATTAAGAAGTTATAATCGAAGTGGTGATTCTGATATCGAGAGGCCTTT 2280

```

NlaIV
Sth132I
CviJI|
SfaNI||
NciI|||
ScrFI|||
SmaI|||
BsaJI|||
MspI|||
NciI|||
Sth132I ScrFI|||
ApoI Bcefi| AvaI|||
Tsp509I MnlI| BsaJI|||
DdeI| HaeIII FokI| BpmI| BsaJI|||
| | | | |
CTTAGAAATTCAAGGGATTGCCGACGGCCTCTTTGTTTCATCAAAATAGCATCCCCGGGGC
2281 -----+-----+-----+-----+-----+-----+-----+-----+ 2340
GAATCTTTAAGTTCCTAACGGCTGCCGGAGAAACAAGTAGTTTTATCGTAGGGGCCCGG

```

HaeIV  
 Hin4I  
 HinfI  
 TfiI  
 ScrFI  
 BanII  
 Bsp1286I  
 EcoRII  
 BciVI  
 SfiI  
 FokI  
 MnlI  
 Tth1111I  
 SfaNI  
 Hpy188I

TCCAGGATTCCGATCAATCTACAGGGTATTEGTTACAAGCATCCTCCGAAAGCTTCTTT  
 2341  
 AGGTCCTAAGGCATAGGTTAGATGTCCGATAAGGAATGTTCTGATGAGGCTTTGAAGAAA  
 2400

TaqI  
 HphI |                      FaeI                      DpnI  
 Bsu36I                      CviRI                      SmaI                      Sau3AI  
 Hpy188IX                      DdeI                      MboII                      AclI                      Hpy188XI  
 |                      |                      |                      |                      |                      |  
 ACATCAGAAAATCTCCTTAGGTTTTGCACAGTTCTTTCACCCGCACTAAAGAAATCGATC  
 2401 -----+-----+-----+-----+-----+ 2460  
 TGTAGTCTTTTAGAGGAATCCAAACGTGTCAAGAAGTGGCGTGATTTCTTTAGCCTAG

[illegible]

FokI

CviJI | | | BccI |  
 HaeI | | | NlaIV | | |  
 HaeIII | | | AvaII | | |  
 StuI | | | CviJI Sau96I | | |  
 FokI | | | TaaI | | | RleAI | HphI | | | BsmFI |  
 CCAAGAGGCCTTTGCAACATCCCACAGTTTAGCGTATGGCTATGGGGACCATCACCTCCA  
 2521 -----+-----+-----+-----+-----+ 2580  
 GGTTCCTCCGGAACGTTGTAGGGTGTCAAATCGCATACCGATACCCCTGGTAGTGGAGGT  
  
 MaeIII  
 Tsp45I | | | AflIII | BsmFI | Fnu4HI  
 MnlI | Hpy178III | MaeII | CviJI | TseI |  
 CGCCTACATCCGTCACATCAAGAACAGGGCAGAAGGGACGTGTTATAGCCATACATTAGC  
 2581 -----+-----+-----+-----+-----+ 2640  
 GCGGATGTAGGCAGTGTAGTTCTTGTCCCGTCTCCCTGCACAATATCGGTATGTAATCG  
  
 AluI | | | BscGI | MnlI |  
 CviJI | BbvI | CviJI | | |  
 Fnu4HI | CviJI | BsaJI | HphI | BbvCI | | |  
 TseI | BbvI | StyI | MboII | Bpu10I | | |  
 AGCAGCTATCGGCTGTTCTTTCCCTTGGCAACAGAAATCCTATCTTCACCTCAGCCCGTT  
 2641 -----+-----+-----+-----+-----+ 2700  
 TCGTCGATAGCCGACAAGAAAGGAACCGTTGTCTTTAGGATAGAAGTGGAGTCGGGCAA  
  
 CjeI  
 MboII |  
 MaeIII  
 Tsp45I | | |  
 MunI | CjeI | Tth111III | | |  
 Tsp509I | MaeII | NspV | | |  
 BseMII | HphI | TaqI | | |  
 Sth132I | CviRI | EarI | | |  
 CGTTCAGGCAATTGCAATACGTTCTCACCAACAGCGTTCGAAGAGATTGGTGACAATCC  
 2701 -----+-----+-----+-----+-----+ 2760  
 GCAAGTCCGTTAACGTTATGCAAGAGTGGTTTGTCTGCAAGCTTCTCTAACCCTGTTAGG  
  
 BsaJI  
 StyI |  
 MnlI |  
 HinfI | |  
 TfiI | |  
 Sth132I | BsmAI | CviJI | Hpy188IX | HinfI | BfaI | | |  
 HphI | | | | | | |  
 CCGAAAGTTTGTCTCTCAAAGCCTTTCTATAATCTGACCTTACCTCTAGGAATCCAAGG  
 2761 -----+-----+-----+-----+-----+ 2820  
 GGCTTTCAAACAGAGAGTTTTTCGGAAAGATATTAGACTGGAATGGAGATCCTTAGGTTCC  
  
 SfcI | Hpy178III | MspI  
 RsaI | BfaI | BsaWI |  
 ApoI | BsaAI | XbaI | BsrFI |  
 Tsp509I | MaeII | PleI | HinfI | PinAI |  
 AAAATGGCAGTCAAATTCACGTACCTACAGAATGGACTCTAGAACTTTCTTACCAACC  
 2821 -----+-----+-----+-----+-----+ 2880  
 TTTTACCGTCAGTTTTAAGGTGCATGGATGTCTTACCTGAGATCTTGAAAGAATGGTTGG

46



3121 ATTGAAATCTTTAGAATTAACAACATATCCGATGAGCTACGTTAGCCCAATCGGTAGAGGA  
-----+-----+-----+-----+ 3180  
TAACCTTAGAAATCTTAATTGTTGATAGGCTACTCGATGCAATCGGGTTAGCCATCTCCT

DraI

MnlI

SwaI

MseI

ApoI ||

Tsp509I ||


| ||

3181 CTCCCTCAAAATTTAAATAA  
-----+-----+ 3200  
GAGGGAGTTTAAATTTATT

80107036-10298

**PRINT OF DRAWINGS  
AS ORIGINALLY FILED**

United States Patent & Trademark Office  
Office of Initial Patent Examination – Scanning Division



**Application deficiencies were found during scanning:**

☐ Page(s) 1 of 1 Document were not present for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Scanned copy is best available.